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Abstract 
North American ginseng is a unique medicinal plant which is believed to show several 
biological activities including: anti-stress, anti-angiogenic, immunosuppressive, and anti-
oxidant activity. Components previously isolated from North American ginseng include 
ginsenosides, polysaccharides, peptides, polyacetylenic alcohols, and fatty acids. The 
biological and pharmacological effects of ginseng are mainly related to the ginsenoside 
components, making their extraction and characterization of interest in order to identify 
them, and study their biological activities.  
This thesis focused on the extraction of ginsenosides from North American ginseng by an 
ultrasonication method with methanol and DMSO as solvents and their aqueous mixtures. 
Quantitative analysis of individual ginsenosides from the extracts was measured by 
HPLC, which demonstrated that ultrasonication significantly enhanced the extraction 
efficiency, with the best efficiency found using 80% solvent (methanol, and DMSO) and 
20% water. Immunosuppressive activity of these ginseng extracts was tested in LPS-
induced macrophage cells showing that the 80% DMSO and 80% methanol extracts gave 
significant potency toward immunosuppressive activity in a dose-dependent manner. 
Moreover, significant quantities of 6”-O-acetylginsenoside Rb1 were obtained using 
DMSO as the extraction solvent during ultrasonication, and identified using MS, FTIR, 
and 1D (1H and 13C) and 2D (gCOSY, gHSQC, and gHMBC) NMR. Also, subsequent 
bioassay experiments confirmed that acetyl ginsenoside Rb1 demonstrated additional 
immunosuppressive activity towards inhibiting the production of nitric oxide (NO) and 
tumor necrosis factor (TNF)-α in LPS-induced macrophage cells in a dose-dependent 
manner using murine macrophages. In addition, acetyl ginsenoside Rb1 gave significant 
anti-angiogenic activity and exhibited enhanced potency towards inhibiting tube-like 
structure formation of endothelial cells. 
Supercritical fluid chromatography (SFC) using supercritical carbon dioxide which is 
considered as a “green” separation method and believed as a promising technique for 
separation, isolation, and identification of herbal and medicinal plants, was used to 
 iii 
 
separate and isolate ginseng extracts obtained by supercritical CO2 extraction (SFE). The 
effect of temperature and pressure on the separation of ginsenosides was studied with 
methanol being added to the CO2 mobile phase. Acidic, basic, and ionic additives were 
introduced to the mobile phase, respectively, to study their effect on the separation of 
ginsenosides. The best separation condition was obtained by adding 0.05% v/v 
trifluoroacetic acid in methanol. A high-concentration component in the extracts from the 
supercritical fluid extraction of North American ginseng was isolated by SFC and 
identified as sucrose using NMR, HPLC, and ESI-MS.  
Because of it's unique biological activities, development of a suitable delivery system for 
acetyl ginsenoside Rb1 (ac-Rb1) was investigated for the first time in this research. PLGA 
microspheres were used to encapsulate ac-Rb1, examining both a double emulsion and a 
microfluidic technique. The size and morphology of the ac-Rb1 loaded PLGA 
microspheres were characterized by SEM and ZEISS light microscopy, showing  
unimodal 50-65 µm size diameters, respectively using the microfluidic technique. Also, 
another delivery system of PLGA in gelatin hydrogel was prepared in order to achieve a 
localized delivery method, overcoming drawbacks such as PLGA removal by 
macrophages and a high initial burst effect from gelatin hydrogel that can damage tissues 
around the injection site. The ac-Rb1 loaded microspheres were incorporated into the 
gelatin hydrogels to form a new delivery system examining gluteradlehyde crosslinking 
concentrations from 10-100µl. FTIR, DSC and TGA confirmed the formation and 
chemical stability of the gelatin encapsulated composites. Release profiles were studied 
and quantified by UV-Vis spectrophotometry with the results showing that the release of 
ac-Rb1 from the unimodal microspheres prepared by the microfluidic technique showed a 
lower initial burst effect than those from the double emulsion method. The burst effect 
was followed by a slow release profile which can be used for long term drug delivery 
applications to maintain the ginsenoside concentration for an extended time period. It 
should be mentioned that although the large burst effect could release a therapeutic agent 
relatively fast, it can also damage tissues around the treatment site. Hence, a combination 
delivery system was developed using cross-linked gelatin. The release of ac-Rb1 from the 
cross-linked gelatin encapsulated microspheres was effected by the pH of the releasing 
medium as well as the crosslinker concentration. Then, the in vitro cumulative release 
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data of the core and core-composite systems was analyzed using empirical equations in 
Matlab. The results showed that the in vitro release kinetics data followed Fickian 
diffusion with the best fit observed using the Weibull model, for all investigated cases. 
Moreover, the released ac-Rb1 from delivery systems showed a significant 
immunosuppressive effect on LPS-induced macrophages indicating the novel delivery 
systems for ac-Rb1 have potential for next-generation biomedical agents in drug-release 
devices. 
 
 
Keywords 
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Chapter 1  
 
1 General Introduction and Literature Review 
 
1.1 Ginseng and Ginsenosides 
Ginseng is one of the perennial plants discovered more than 5,000 years ago in the 
mountain provinces of Manchuria. It is currently one of the best-selling medicinal plants 
in the world [1, 2]. There are different types of ginseng that have been discovered 
depending on their cultivation area; the most important being Panax ginseng (Korean or 
Asian), Panax quinquefolius (American), Panax notoginseng (Tienchi or Sanchi), Panax 
Japonicus (Japanese) and Panax vietnamensis (Vietnamese) [3]. North American ginseng 
grows in the northern areas of the United States and within both British Columbia and 
Ontario provinces of Canada. Native North Americans used the roots of this plant as a 
part of traditional medicine for relieving fever and stomach misery [4]. Successful 
cultivation of North American ginseng started from the 1800s. Nowadays ginseng is one 
of the most popular medicinal plants available as a herbal medicine; or nutritional 
supplement. Ontario produces around 2,000 tonnes of ginseng root annually, 90% of 
which is exported for commercial use to Asia. According to Agriculture and Agri-Food 
Canada, Canada exports about 3,000 tonnes of North American ginseng roots annually to 
China and other Asian markets, especially Hong Kong. The price of ginseng exports to 
all countries in total had 26.8% growth from 2007-2010 [5]. 
The extracts of this herbal plant have been studied and are known to have abundant 
beneficial health effects on the central nervous, cardiovascular, endocrine, and immune 
systems. Ginseng in general is composed of the active ingredients, saponins, called 
ginsenosides, polysaccharides, peptides, polyacetylenic alcohols, fatty acids, sugars, 
amino acids, vitamins and minerals. The most active ingredients found in ginseng are 
ginsenosides, with more than 60 different kinds of ginsenosides being extracted and 
identified from different parts of North American ginseng plants [1]. The ginsenoside 
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composition varies depending on which part of the plant is used such as the roots, leaves, 
stems, flower buds and berries. The ginsenoside content in the leaves of North American 
ginseng has been reported to be between 1.9-4.2% of the dry weight, whereas it varies 
between 3-7% of the dry weight in the root [1]. The structure of different ginsenosides 
isolated from North American ginseng are shown in Figure  1.1. 
 
 
Figure  1.1. Core structures of different types of triterpenoid saponins from American 
ginseng [6]. 
Differences in ginsenoside composition exist between the various types of ginseng. For 
instance, North American ginseng contains Rb1, Re, Rd, Rc, Rg1 and Rb2 while it  does 
not contain ginsenosides Rf and Rg2. In comparison, Asian ginseng includes low 
concentrations of Rf and Rg2. The other useful factor that can help to distinguish 
American from Asian ginseng is the ratio of Rg1/Rb1 and Rb2/Rb1. American ginseng 
exhibits both Rg1/Rb1 and Rb2/Rb1 ratios less than 0.4, whereas Asian ginseng shows 
higher ratios. Major ginsenosides identified in North American ginseng consist of 
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protopanaxidiol type (PPD) that has sugar moieties attached to the β-OH at C-3 and/or C-
20 and protopanaxtriol type (PPT) that has sugar moieties attached to the α-OH at C-6 
and/or β-OH at C-20. Four malonyl derivatives (also called “acidic” ginsenosides) have 
been isolated from North American ginseng. Minor ginsenosides isolated from North 
American ginseng include ocotillol-type and oleanane-type ginsenosides. Other extracted 
ginsenosides can be categorized as modified C-20 side chain ginsenosides, which can be 
divided into nine groups due to C-20 side chain differences. Malonyl-ginsenosides which 
have a malonic acid functionality at the R1 group (C-6 of the terminal glucosyl ring) 
attached to C-3 in the PPD structure (Figure  1.1) such as malonyl mRb1, mRb2, mRc and 
mRd are more polar and water soluble than original ginsenosides.  
The malonyl-ginsenosides are unstable ginsenosides that are changed to neutral 
ginsenosides by hydrolysis, demalonylated by heat, or catalyzed by both acid and base. 
As other examples of thermal instability, ginsenosides Rg3, Rh2, and Rg5 have been 
shown to have anti-cancer applications and are the thermal degradation products of 
neutral ginsenosides not naturally found in North American ginseng [6]. Polar 
ginsenosides often become less polar during the steaming or heating process due to 
structural changes of the sugar moieties. Moreover, it has been shown that ginsenosides 
can be degraded into novel structures using microbes, enzymes and intestinal bacteria 
within animals and humans [7]. For instance, ginsenoside Rb1 is metabolized to 
compound K via biotransformation which has higher bioactivity as shown in Figure  1.2.  
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Figure  1.2. Proposed biotransformation pathway of ginsenoside Rb1 to compound K [8, 
9]. 
1.2 North American ginseng biological and pharmacological 
activities 
Ginseng is one of the best-selling herbal plants in the world with more than six million 
Americans consuming ginseng products to enhance resistance to physical, chemical and 
biological stress and improve general vitality [1]. Similar to Asian ginseng (Panax), 
American ginseng has been shown to provide various pharmacological activities such as 
antioxidant, anti-inflammatory and immunostimulatory activities. It is believed that most 
of the ginseng biological activities are related to the ginsenoside components, which are 
the main active components of ginseng root. Other ginseng ingredients such as 
polysaccharides, polypeptides, polyacetylenes, and alkaloids have been shown to 
participate in biological activity. The isolated diacetylenes, mainly panaxytriol, 
panaxynol, and panaxydol, demonstrate cytotoxic, antiplatelet and anti-inflammatory 
activities, respectively [10]. Also, quinquefolans A-C from American ginseng have 
demonstrated marked blood glucose-lowering effects after administration to both normal 
and alloxan-induced hyperglycemic mice [10]. Wang et al have shown a hypoglycemic 
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effect of ginseng polypeptides [11]. In vitro studies on polysaccharide extracts from 
American ginseng have shown stimulation of the proliferation of normal mouse spleen 
cells, of which the major responding subpopulation was identified as B lymphocytes. 
This American ginseng polysaccahride extract activated peritoneal exudates macrophages 
and increased interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), 
and nitric oxide (NO) production. Moreover, it stimulated in vivo immunoglobulin G 
(IgG) production in treated mice [12]. A following ex vivo study using C57 BL/6 mice 
implied that the polysaccharide extract is capable of increasing Con-A-induced IL-2 and 
IFN-γ production in spleen cells in a dose-dependent manner. A study by Azike et al. also 
supported the previous results that North American polysaccahride extracts show an 
immunostimulatory effect both in vitro and in vivo [13]. Several studies have evaluated 
the anti-inflammatory activity of ginsenosides and their metabolites. For instance, 
ginsenosides Re and Rg1 are transformed to ginsenoside Rh1 or 20(S)-protopanaxatriol, 
which showed anti-inflammatory effects [14]. Park et al. examined the anti-inflammatory 
activity of ginsenoside Rb1 isolated from Panax ginseng and its metabolite compound K 
on LPS-induced RAW264.7 cells. Their results demonstrated that compound K and not 
ginsenoside Rb1 inhibited the production of NO in LPS-induced RAW 264.7 macrophage 
cells [15]. Park el al. also reviewed the in vitro and in vivo anti-inflammatory effects of 
ginsenosides and their metabolites. While ginsenosides Rb1 and Rb2 were shown to 
inhibit TNF-α production by LPS-stimulated RAW264.7 murine or U937 human 
macrophages in a dose-dependent manner, ginsenosides Re and Rg1 did not show any 
potency [16]. Similarly, ginsenosides Rb1, Rc or Re did not inhibit NO production by 
LPS-stimulated RAW264.7 cells [17]. Another study reported on the anti-inflammatory 
effects of ginsenosides on the inhibition of various inflammatory molecules such as 
PGE2 (produced by COX-2) by murine or human macrophages, isolated from Panax 
ginseng [17].  
Based on the various pharmacological effects of North American ginsenosides [1], their 
biological activity can be summarized as shown in Figure  1.3. 
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Figure  1.3. Biological and pharmacological activities of North American ginsenosides 
[1]. 
As can be seen in Figure  1.3, North American ginsenosides have been shown to provide 
beneficial effects on aging, central nervous system (CNS) disorders, and 
neurodegenerative diseases [18]. Specifically Rb1, Rg1, Rg3, Rd, and Re effects on 
neurodegeneration have been examined in animals and in neuronal cell cultures [19-23]. 
Moreover, North American ginseng and ginsenosides are believed to increase cognitive 
performance and mood [24-26]. They are also believed to provide increased neuronal cell 
survival, extending neurite growth, and rescuing neurons from death either in vivo or in 
vitro. Their effect on neurodegenerative disease models of Parkinson’s and Alzheimer’s 
diseases have also been investigated [27]. 
The antioxidant property of North American ginseng has been shown to affect 
cardiovascular activity [28]. This herb has also demonstrated anti-ischemic, 
antiarrhythmic and anti-hypertensive effects [29]. The major antioxidant agent of North 
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American ginseng, ginsenoside Re, has been found to protect cardiomyocytes by 
scavenging H2O2 and hydroxyl radicals [30].  
American ginseng and ginsenosides have also been shown to have cancer prevention 
activity by increasing the chemopreventive effect of 5-fluorouracil in human colon cells, 
the chromosomal aberration suppression induced by mitomycin C in mice, cancer related 
fatigue improvement, and radioprotective potential production in the lymphocytes of 
healthy individuals [1]. Due to the complexity of the anticancer mechanisms of ginseng, 
most studies have examined individual ginsenosides, but not North American ginseng 
extract or acetylated ginsenosides.  
1.3 Extraction of bioactive compounds 
Extraction of bioactive components from natural plants such as ginseng has attracted 
significant attention in recent years. Separation of bioactive compounds is possible 
utilizing a suitable extraction method. The available extraction methods are used to 
extract the bioactive compounds from natural plants, and can enhance the selectivity of 
analytical methods. Also, various extraction methods are common for the purpose of 
increasing sensitivity of a bioassay by enhancing the targeted component concentration. 
In addition, all extraction methods are desired to provide a reproducible technique that is 
not affected by variations in the plant matrix [20]. 
1.3.1  Methods for extraction of ginsenosides from North American 
ginseng 
The ginsenoside content in NA ginseng has been shown to be sensitive to the extraction 
technique and to the solvents used [31]. The conventional methods of solvent extraction 
are mainly based on the choice of solvent and the use of heat and/or mixing to increase 
the solubility of materials and the rate of mass transfer [32]. Traditional extraction 
methods such as Soxhlet are time consuming and require large amounts of organic 
solvents. By increasing the demand for reducing the extraction time and the organic 
solvent consumption, novel extraction methods such as pulsed-electric field extraction 
[11, 20, 33], enzyme-assisted extraction [20, 34, 35], ultrasound assisted extraction [32], 
microwave assisted extraction [36-38], supercritical fluid extraction [39-41], and 
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accelerated solvent extraction [32, 42, 43] have been utilized for the extraction of 
medicinal and biological components from herbal plants like ginseng [32, 44]. Below we 
will examine Soxhlet, ultrasound-assisted and supercritical fluid extraction which were 
utilized in this thesis. 
1.3.1.1 Soxhlet extraction method 
In Soxhlet extraction, as a standard and reference technique, the plant material is firstly 
placed in a cellulose thimble, and then placed in the Soxhlet distillation apparatus which 
is filled with condensed fresh solvent from a distillation flask after the solvent reaches the 
boiling point. After the solvent reaches the overflow level, a siphon starts to remove the 
solvent carrying the extracted material into the distillation flask. The solute is separated 
by means of distillation and remains in the flask and the solvent again passes back to the 
solid bed in the thimble. This procedure is repeated until the extraction is complete [32]. 
The main disadvantages of conventional Soxhlet extraction include: (1) the long 
extraction times; (2) a large amount of solvent is used; (3) agitation cannot be provided to 
intensify the process; (4) the large amount of solvent used needs an 
evaporation/concentration process; and (5) the possibility of thermal decomposition of 
materials as the extraction often happens at the boiling point of the solvent. However, this 
method is used for ginsenoside extraction usually as a reference method [2]. 
1.3.1.2 Ultrasound-assisted extraction 
Ultrasound-assisted extraction is an inexpensive, simple and efficient alternative to 
conventional extraction techniques [32]. In ultrasound-assisted extraction, the extra 
external energy helps to increase mass transfer compared to conventional solvent 
extraction. The extraction mechanism by ultrasound consists of two physical phenomena. 
First, the diffusion across the cell wall and second the rinse of the cell contents after the 
walls are broken [20]. Natural plant characteristics such as the moisture content of the 
sample, milling degree, particle size and the solvent used in the extraction process are 
very important factors. Besides temperature, pressure, frequency and sonication time are 
important factors for the action of ultrasound. The main advantage of ultrasound in plant 
extraction is an increase of the extraction yield and faster kinetics. Ultrasound can also 
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decrease the operating temperature so it is a good technique for thermally unstable 
compounds. This method can also be used with a wide range of solvents for the 
extraction of natural compounds. However, the effects of ultrasound on extraction yield 
and kinetics may be related to the nature of the plant matrix. Wu et al. [45] evaluated the 
ultrasound-assisted extraction for separation of ginsenosides from both Panax ginseng 
and American ginseng and found that this extraction method is three times faster than 
traditional extraction methods such as Soxhlet. Moreover, many researchers have used 
the ultrasound-assisted extraction method as a comparison with other methods under 
different conditions [46, 47]. 
1.3.1.3 Supercritical fluid extraction 
A supercritical fluid is a fluid which exists at a pressure higher than its critical pressure 
and a temperature greater than its critical temperature. A phase diagram of a supercritical 
fluid is illustrated in Figure  1.4. A liquid-like density of a supercritical fluid and its gas-
like viscosity and higher diffusivity than liquid (as shown in Table  1.1) make 
supercritical fluids enabling solvents for extraction with sufficient solvation power and 
excellent mass transfer characteristics.  
 
Figure  1.4. Schematic of the phase diagram of a single substance [48]. 
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Table  1.1. Typical properties of gas, liquid, and supercritical fluids [48]. 
Property Units Gas  
1atm, 25°C 
Liquid  
1atm, 25°C 
Supercritical fluid 
Tc, Pc Tc, 4Pc 
Density ρ (g cm−3) 0.6-2×10−3 0.6-1.6 0.2-0.5 0.4-0.9 
Diffusivity Dm (cm2s−1) 1-4×10−1 0.2-2×10−5 0.5-4×10−3 0.1-1×10−3 
Viscosity µ(g cm−1s−1) 1-3×10−4 0.2-3×10−2 1-3×10−4 3-9×10−4 
 
In Table  1.2, the critical properties of different materials used as supercritical solvents are 
shown. The most commonly used supercritical fluid is supercritical carbon dioxide, 
which is non-toxic, non-flammable, inexpensive, naturally abundant, chemically stable 
and has a convenient critical temperature (31.1°C) and pressure (73.8 bar) [49]. In 
addition, it is environmentally friendly (i.e. is not a volatile organic compound (VOC)), is 
a byproduct of fermentation, and has lower operation costs due to lower energy 
consumption. 
Table  1.2. Materials useful as supercritical fluids [50]. 
Materials Tc (K) Pc (bar) ρc (g cm−3) 
Ethylene 282 50 0.22 
Xenon 290 58 1.11 
Fluoroform 299 49 0.53 
Carbon dioxide 304 74 0.47 
Ethane 305 49 0.20 
Nitrous oxide 310 72 0.45 
Propane 370 43 0.22 
Ammonia 406 114 0.23 
Water 647 221 0.32 
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Tc, Pc and ρc are critical temperature, critical pressure and critical density, respectively. 
 
Moreover, one of the most significant benefits of supercritical solvents is their solvation 
power, which can be tuned by changing the pressure and and/or temperature. Therefore, 
the solubility of the solute in the supercritical solvent can be decreased or increased by 
enhancing or reducing the pressure and/or temperature [49]. This property is 
advantageous in the selective separation and isolation of bioactive components from 
natural herbal plants.  The main disadvantage of using pure supercritical CO2 for 
separation and chromatography is the poor solubility of polar components in Sc-CO2 
[32]. To encounter this lack of solubility, modifiers such as methanol, ethanol and 
acetone are used to increase the solubility of materials in the supercritical CO2.  
The supercritical fluid extraction (SFE) technique is one of the most environmentally 
responsible and effective methods for the extraction of novel medicinal compounds from 
herbal plants. The application of a supercritical fluid for extraction applications was 
established with its discovery by Hannay and Hogarth (1879) [51]. However Zosel is also 
associated with the discovery of SFE by presenting a patent for decaffeination of coffee 
using SFE. Using this technique, selective extraction can be obtained since the solubility 
of a chemical in a supercritical fluid (SCF) can be manipulated by changing the pressure 
and/or temperature of the fluid. Moreover, the solute solubility in the SCF is enhanced 
with the density of the fluid that can be obtained at higher pressures. By reducing the 
SCF density during depressurization, the dissolved components can be recovered. 
Furthermore, the SCF diffusivity is one to two orders of magnitude higher than that of 
other liquids, thus increasing the mass transfer rate, and enhancing the extraction yield. 
Additionally, the low supercritical temperature of CO2 makes it more useful for the 
extraction of thermally unstable compounds. Due to a minimum use of organic solvents 
in SFE, this method can be applied as an environmentally friendly extraction process 
compared to other conventional methods. By adding modifiers such as methanol to the 
SCF, its polarity can be increased for gaining more selective separation power. However, 
the economics and difficult operating conditions of the SFE method made some 
limitations in it's application. Many researchers have worked on the SFE method to 
extract plant materials, including lipids [52], and essential oils [53-55]. In addition, 
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extraction of biologically active components from plants has been carried out in previous 
studies [39-41]. In 2001, Wang et al. [2] evaluated a semi-continuous supercritical CO2 
process for ginsenoside extraction from Panax ginseng root in the presence of ethyl 
alcohol as the co-solvent. The authors implied that the crude oil extraction yield increased 
with pressure at constant temperature, and was only enhanced with temperature when the 
pressure was above 24.2 MPa. Wood et al. [31] demonstrated ginsenoside extraction 
from North American ginseng root by means of supercritical CO2 extraction in the 
presence of methanol and DMSO as modifiers. The authors investigated the optimal 
conditions to obtain the maximum amount of target ginsenosides and found that the 
modifier had a significant effect on ginsenoside selectivity. Also, at constant pressure, 
temperature and modifier percentages, increasing flow rate was found to have no 
significant effect on the extraction yield. Furthermore, they found that in the presence of 
both methanol and DMSO as modifiers during supercritical CO2 extraction, relatively 
large amounts of a novel mono-acetylated ginsenoside was detected providing potential 
for a higher bioactivity extract [31]. 
1.3.2 Comparison of different extraction methods for selected 
bioactive components from natural plant 
In order to achieve the most effective and selective extract, several factors should be 
investigated including: the characteristics of the natural herbal plant and its bioactive 
components, the solvents used for extraction and the extraction method applied. It is 
important to know that a high yield of extract will not always guarantee a high yield of 
bioactive components in the extract. The extraction method should be carefully 
considered for separation of bioactive components which are sensitive to oxygen and 
heat. Moreover, the yield and quality of bioactive components should be taken into 
consideration when an extraction method is chosen [32]. 
1.4 Quantification and separation of bioactive components 
from natural herbal plants 
There is an increasing demand for highly sensitive and selective analytical methods for 
the determination of ginseng extracts. The analytical methods can be used for either the 
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total saponin content determination or for analysis of the target compound, e.g. the 
analysis of a specific ginsenoside [19]. Also, some studies have evaluated the group-
specific analysis, i.e. the analysis of a number (preferably all) ginsenosides. Others have 
used analytical methods for metabolite fingerprinting that exhibit a large number of 
primary and secondary metabolites from the extract, and contain (besides the 
ginsenosides) carbohydrates, lipids, amino acids, etc. [19]. 
1.4.1 Chromatographic techniques used in separation, qualitative 
and quantitative analysis 
Various methods for the identification and quantification of ginsenosides in ginseng have 
been investigated. Ginsenoside fractionation has been obtained using both thin layer 
chromatography (TLC) and gas chromatography, although high performance liquid 
chromatography (HPLC) is the most widely used method. Due to HPLC's speed, 
sensitivity and compatibility with non-volatile polar materials; this technique is a precise 
method for saponin analysis. The chromatographic conditions of the HPLC method 
includes the use of, almost exclusively, a reversed-phase C18 column; a UV–Vis diode 
array detector, and a binary solvent system containing water (solvent A) and a polar 
organic solvent (solvent B). Reverse phase (RP) HPLC has become an important 
analytical tool for the separation and determination of ginsenosides with different 
detection systems, such as diode array detector (DAD), mass or tandem mass 
spectrometry. Evaporative light scattering (ELSD) and fluorescence were utilized with 
HPLC for ginsenosides detection [56]. Furthermore, new techniques such as near infrared 
spectroscopy (NIRS) and enzyme immunosassay (EIA) were recently used for the 
determination of ginsenosides [3]. Nuclear magnetic resonance spectroscopy (NMR) and 
mass spectrometry [22] are also valuable techniques used for interpretation of chemical 
structures of molecules, such as ginsenosides or other bioactive unknown compounds in 
ginseng extract [57-59]. Most of the literature available on ginsenoside extract 
identification has been analyzed by HPLC [56, 60, 61]. 
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1.4.1.1 Supercritical Fluid Chromatography (SFC) 
Supercritical fluid chromatography (SFC) is a relatively recent chromatographic 
technique used in the separation and identification of bioactive compounds from natural 
plants. SFC can be depicted as a chromatography system with similarities to both HPLC 
and GC, however the mobile phase is a supercritical fluid [49]. The first work on SFC is 
considered to be in 1962 by Kleper et al. The expansion of SFC during this period was 
slow compared to the rapid growth of HPLC which happened at about the same time 
[49]. The major increase in SFC use happened during the 1980s [49]. The number of 
publications on SFC represented in Figure  1.5 covers the academic literature from 1962-
2012 [48]. 
 
 
Figure  1.5. Number of publications on supercritical fluid chromatography [48]. 
By using SFC, the amount of organic solvents commonly used in HPLC is reduced, thus 
this method can be considered a “green” technique. Moreover, in comparison to HPLC, 
separations can be faster by means of SFC because the diffusion of solutes in 
supercritical fluids is about ten times greater than that in liquids (and about three times 
less than gases). Compared with GC, capillary SFC can provide high resolution 
chromatography at much lower temperatures. This allows fast analysis of thermolabile 
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compounds [49]. Column technology and instrumentation research were very dynamic in 
the 1980s, leading to commercialization of SFC instruments. Normally, packed-columns 
are used for SFC with binary or ternary fluids as the mobile phase, composition 
programming, and a UV detector. Stationary phases used in packed-column SFC systems 
show higher surface areas to void volume ratios than capillaries and are much more 
retentive [48]. The SFC system is flexible due to its compatibility with multiple detectors 
such as UV, ELSD, and MS [48]. ELSD is a universal detector used in both HPLC and 
SFC usually for compounds with low UV absorption. In packed-column SFC, researchers  
have investigated  organic modifiers in high percentage added to the CO2 as mobile phase 
to increase the solvation power. Then, under regularly used chromatographic conditions 
such as 100-120 bar pressure and 40°C temperature, the mobile phase fluid is not in a 
supercritical state. However, SFC researchers use the phrase supercritical fluid 
chromatography despite the real state of the fluid employed [49]. In addition, research 
has demonstrated that preparative SFC can be utilized as a rapid isolation method in the 
separation and fractionation of unknown bioactive compounds for spectroscopic 
identification in pharmaceuticals and nutraceuticals [48, 49]. 
SFC has been reported in the literature as a useful tool in natural product applications and 
drug discovery. In drug analysis, the only study that used SFC to separate ginsenosides 
from ginseng extracts was reported by Li et al. [62]. They only used pure CO2 as the 
mobile phase and pressure gradient from 100 to 350 bar and temperature of 300°C with a 
flame ionization detector to separate panaxadiol and panaxatriol saponins from ginseng.  
Although there is essentially no other studies on the SFC of ginseng itself, there is a large 
amount of literature regarding the use of SFC analysis for other natural products. Natural 
compounds such as resin acids, triterpenoid compounds (important in the cosmetics 
industry), glycolipids and phospholipids and carbohydrates, and ginko terpene trilactones 
were analyzed with SFC. Most of these research investigations used different columns, 
mobile phase modifiers and additives, and chromatographic conditions to obtain rapid 
high resolution isolation [63-68]. Buskov et al. [69] used SFC with methanol as a 
modifier for the determination and quantification of the different indol-3-ylmethyl, which 
has anticarcinogenic effects, including ascorbigens. They also investigated myrosinase 
catalysed degradation of 4-hydroxybenzylglucosinolate (sinalbin), which has anti-
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nutritional and cancer preventive effects. Sinalbin occurs as an important glucosinolate in 
the seeds of Sinapis alba L., in different mustards and other food products [70]. In a 
separate study [71], they used SFC with CO2-ethanol to isolate and identify 
furocoumarins, which are natural plant metabolites, mainly obtained from the 
Umbelliferae (celery, parsnip, parsley) and Rutaceae (citrus plants). The authors 
demonstrated that SFC identified the essential oil composition in a short time (around 10 
min). Recently, Lesellier et al. [23] used SFC coupled with ELSD as a high resolution, 
fast analysis technique for separation of triperpenoids in natural plants that posses 
different biological activities such as anti-bacterial, anti-oxidant, anti-inflammatory, and 
anti-tumor. They tested various stationary phases, modifier percentage, from 10 to 30%; 
backpressure (from 120 to 180 bar) and temperature (from 15 to 25 °C) to improve the 
separation [23]. 
1.5 Delivery systems for herbal formulations 
Over the past several years, significant progress has been directed for the improvement of 
novel delivery systems for bioactive compounds from plant extracts and natural health 
products such as nutraceuticals, probiotics, and traditional Chinese medicines [72]. These 
plant based formulations include tablets, capsules, teas, creams, oils, and liquids which 
consist of a mixture of generally low concentrations of biologically active compounds. 
These plant based extracts work more slowly and gently than pharmacologic drugs, and 
are less likely to cause serious side effects and toxicity. Recently, different formulations 
such as polymeric nanoparticles, nanocapsules, liposomes, phytosomes, nanoemulsions, 
microsphere, transferosomes, and ethosomes have been investigated for bioactive and 
plant extract delivery [73-75]. These novel systems have significant advantages over 
conventional delivery of plant actives and extracts although require basic development of 
pharmacological activity and sustained delivery. 
1.5.1 Microencapsulation techniques for bioactive extracts from 
herbal plants 
One of the potential delivery carriers for bioactive compounds of plant extracts is 
polymer microspheres. There are various microencapsulation synthetic methods for 
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bioactive compounds. Choosing the best method depends on several factors such as 
polymer and drug characteristics, the site of action and therapy administration. The 
preparation process should be in a way that assures the chemical stability and biological 
activity of the encapsulated material. The encapsulation efficiency and the yield of the 
microspheres as well as the uniform size distribution of microspheres should be 
consistent with the targeted end-use. Furthermore, the encapsulation process should yield 
reproducible results and the release profile should be in agreement with the application 
requirements. Emulsion-solvent evaporation/extraction methods are widely used as an 
encapsulation method for bioactive compounds using either the so-called single emulsion 
or double emulsion methods [76-78]. Usually microspheres consist of either synthetic 
biodegradable polymers or natural polymers. Synthetic polymers used as a microsphere 
carrier usually contain poly-α-cyanoacrylate alkyl esters, polyvinyl alcohol, polylactic 
acid, and polylacticcoglycolic acid, etc. Whereas the natural polymer as a microsphere 
carrier typically includes either proteins (albumin, gelatin and vegetable protein) or 
polysaccharides (cellulose, starch and its derivatives, alginate, chitin and chitosan, etc.). 
So far, a series of plant active ingredients as shown in Table  1.3 has been made into 
microspheres. It should be mentioned that delivery of bioactive extracts may need other 
administration routes rather than oral such as parenteral formulations in order to prevent 
degradation in the digestive tract and first pass metabolism. Therefore, the injectable 
and/or transdermal biodegradable and biocompatible PLGA microparticles can 
potentially be used for bioactive and natural herbal products delivery.  
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Table  1.3. Microspheres encapsulated herbal formulations [73]. 
Formulation Active 
ingredients 
Applications Biological 
activity 
Administration 
route 
Rutin–
alginate– 
chitosan 
microcapsules 
Rutin Targeting into 
cardiovascular region 
Cardiovascular 
diseases 
In vitro 
Zedoary oil 
microsphere 
Zedoary oil Sustained release and 
higher bioavailability 
Hepatoprotective Oral 
CPT loaded 
microspheres 
Camptothecin Prolonged-release of 
camptothecin 
Anticancer Intraperitoneally 
and intravenously 
Quercetin 
microspheres 
Quercetin Significantly decreases 
the dose size 
Anticancer In vitro 
Cynara 
scolymus 
microspheres 
Cynara 
scolymus 
extract 
Controlled release of 
neutraceuticals 
Nutritional 
supplement 
Oral 
1.5.1.1 PLGA as biodegradable delivery carrier 
Polyester PLGA is a FDA-approved biodegradable polymer that is a copolymer of poly 
lactic acid (PLA) and poly glycolic acid (PGA). Due to its long clinical experience, high 
biocompatibility, appropriate degradation characteristics and possibilities for sustained 
drug delivery, PLGA is one of the most well-known biodegradable polymers that have 
been studied as delivery carriers for drugs, proteins, and peptides. Based on its 
physicochemical properties, PLGA can be formed into any shape and size, and can be 
used to encapsulate a variety of materials. Moreover, the overall physical properties of 
the PLGA-bioactive compound system can be adjusted by controlling parameters such as 
polymer molecular weight, ratio of lactide to glycolide and bioactive compound 
concentration in order to obtain a desired release behavior. As can be seen in Figure  1.6, 
biodegradation of PLGA occurs by hydrolysis of its ester linkages into oligomers and, 
finally monomers, lactic and glycolic acids. Lactic acid can be metabolized and 
subsequently eliminated from the body as carbon dioxide and water. Glycolic acid can 
also be excreted unaffected by the kidneys or can be metabolized and ultimately 
eliminated as carbon dioxide and water. Moreover, lactic acid is more hydrophobic than 
glycolic acid due to presence of methyl groups. As a result, when the ratio of lactide to 
glycolide is higher, PLGA shows more hydrophobicity and the degradation process 
lowers. Therefore, the release and degradation rates of encapsulated bioactive compounds 
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will be effected by changes in PLGA properties during the polymer biodegradation 
process [79].  
 
 
Figure  1.6. Hydrolysis of poly lactic-co-glycolic acid [79]. 
Conventional microencapsulation methods generate microspheres with broad size 
distributions influences the kinetics of encapsulant release and limits their clinical 
application [80]. Recently, microfluidic devices have attracted attention due to the 
adjustability to create microspheres with controlled morphology [81]. Microfluidic 
devices utilize low-priced and convenient systems for the control of fluid flow [82]. A 
large number of microfluidic devices are engineered by poly(dimethyl) siloxane (PDMS), 
a fairly inexpensive and simply moldable elastomeric polymer. Other materials with 
greater solvent resistance such as glass and silicon have been used due to swelling and 
deformation of PDMS in the presence of strong organic solvents. 
In general, the microsphere generation process relies on different parameters, including 
the flow rates of dispersed and continuous phases, the interfacial tension between the 
fluids and the wetting effect of the channel wall, of which the last two are difficult to 
adjust experimentally [83]. In order to avoid adherence to the channel walls, the 
hydrophilic inner wall of a microfluidic device are treated with silanization and 
siliconization to provide hydrophobic channels for water/oil (W/O) droplets. The surface 
wettability can also be changed by adding surfactants such as Span 80 and Tween 20 
[84]. Moreover, surfactants are employed to avoid unwanted coalescence between 
microspheres by decreasing the surface tension between the continuous and disperse 
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phases. Two significant type of microfluidic devices used for monodisperse particles 
generation are T-junctions [85] and flow-focusing [82] which are dependent on the 
channel geometry for controlling monodisperse particles which can be shown in Figure 
 1.7.  
 
 
Figure  1.7. Droplet formation with different mechanisms: (a) Flow focusing; (b) T-
junction [86].  
In the T-junction device, the inlet channel including the dispersed phase vertically crosses 
the main channel which contains the continuous phase (Figure  1.7b). The droplet sizes 
can be "tuned" by adjusting the fluid flow rates, the channel widths, or by altering the 
relative viscosity between the two phases. In the flow-focusing geometry, the dispersed 
and continuous phases are carried to a narrow section in the device (Figure  1.7a). The 
sizes of the droplets are decreased by increasing the flow rates of the continuous phase. 
Different factors such as geometry of the device, the viscosity of the disperse and 
continues phases, use of surfactants, and hydrophilicity or hydrophobicity of the channel 
surface have an effect on the size ranges of formed droplets [87]. 
Monodisperse microspheres made from biodegradable polymers have been generated by 
microdluidic devices widely used in drug delivery systems [80]. Xu et al. [82] used a 
flow-focusing microfluidic device for encapsulation of a model amphiphilic drug 
(bupivacaine) with a size of 11 µm and 41 µm. The size of the microspheres have been 
shown to be control with the disperse and continuous phases flow rate. Also, the kinetics 
of drug release show that the release profile from monodisperse microspheres is slower 
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than that from the conventional methods followed by a lower initial burst. Moreover, He 
et al. [80] modified a microfluidic chip for encapsulation of paclitaxel within poly(L-
lactic acid) microspheres. They modified a PDMS surface by using poly(vinyl 
alcohol)/glycerol (PVA/Gly) solution immersion in order to produce monodisperse 
droplet within a range of different sizes depending on the relative flow rates. However, 
there is no study available regarding to the fabrication of monodisperse microspheres 
containing bioactive plant extract.  
1.5.2 Release behavior and modeling approach 
The rationale for using controlled release systems is to preserve active component 
concentration in the blood or in target tissues at a desired value for as long as possible. 
The concentration of the active component in the blood circulation varies over successive 
doses of most conventional formulations due to fast release right after administration (i.e. 
burst release effect). Therefore, the concentration of drug or herbal extract in blood rises 
quickly to a high value (peak) followed by a rapid decrease to a very low value (trough) 
due to component elimination (Figure  1.8). In fact, the therapeutic window is the range of 
concentration that causes an optimal therapeutic effect with concentrations above this 
range leading to side effects while concentrations below this range may result in 
decreased efficacy. The object of many controlled release technologies is to lessen the 
time during which the concentration of active component is above or below the 
therapeutic window, while lengthening the duration of the active component’s existence 
within the desired concentration range. 
 Figure  1.8. Release profile for conventional and controlled release within effective 
concentration region [88]
The release mechanism of the active pharmaceutical ingredient (API) has been used with 
different definitions. True release mechanisms refer to the way in which a drug is 
released while rate-controlling release mechanisms refer to the processe
drug release rate. There are four true release mechanisms including diffusion through 
water filled pores, diffusion through the polymer, osmotic pumping and erosion (i.e. no 
drug transport) as shown 
 
Figure  1.9. True release mechanisms: A) diffusion through water filled pores, B) 
diffusion through the polymer, C) osmotic pumping and D) erosion 
 
. 
in Figure  1.9.  
[89]. 
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The complex picture of the different parameters that have an affect on the drug release 
from PLGA is shown in Figure  1.10. The rate-controlling release mechanisms including 
water absorption or swelling, dissolution, hydrolysis, erosion, drug-polymer interaction, 
etc. seem to be more informative in order to modify how a drug can release. However, 
due to the complexity of the delivery system it is not generally clear which of the 
processes is governing and which are rate-governing for API release.  
 
 
Figure  1.10. The complex picture of various parameters that effect drug release from 
PLGA matrices [89].  
Mathematical modeling is a very useful tool to predict controlled release in order to 
understand the mechanism of release. A diversity of mathematical models have been 
investigated for drug release. These can be categorized into two main groups: 
empirical/semi-empirical models and mechanistic mathematical models [89]. 
Empirical/semi-empirical models are simply mathematical explanations, and are not 
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based on any real chemical, physical or biological phenomenon. Several methods can be 
employed as empirical/semi-empirical models such as the Peppas, Higuchi, and Weibull 
models. These methods are useful, for instance, in representing diverse phases of the drug 
release, which are useful in product development [72, 80, 90]. However, mechanistic 
mathematical models are derived from real phenomena, such as diffusion, degradation 
and erosion, and are useful tools for a detailed understanding of the release process.  
 
1.6 Scope of the research 
Since ginsenosides can be selectively extracted from North American ginseng and 
actively targeted to various disease areas; different extractions, characterizations and 
bioassays should be used to test this hypothesis. 
The following were identified as specific objectives of this project: 
I. Ultrasound-assisted extraction of North American ginseng with DMSO and 
methanol as solvents. 
 
II. Isolation and identification of 6”-O-acetylginsenoside Rb1 extracted from 
North American ginseng. 
 
III. Study the Immunosuppressive and Anti-angiogenic effects of 6”-O-
acetylginsenoside Rb1 extracted from North American ginseng. 
 
IV. Analyze of North American ginseng extract using supercritical fluid 
chromatography. 
 
V. Encapsulation of acetyl ginsenoside Rb1 within monodisperse PLGA 
microspheres using microfluidic technique. 
 
VI. PLGA microspheres crosslinked gelatin hydrogels systems for acetyl 
ginsenoside Rb1 delivery. 
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Chapter 2  
 
2 Ultrasound Assisted Extraction of North American 
Ginseng and Isolation of 6”-O-acetylginsenoside 
Rb1, Immunosuppressive and Anti-angiogenic 
Effects 
 
Abstract 
Extraction of medicinally-active components from natural health products has become an 
emerging source for drug discovery. Of particular interest for this work was the finding 
and testing of new ginsenosides from North American ginseng (Panax quinquefolius). In 
the present study, the yield and selectivity of ginsenoside extraction from North 
American ginseng root was determined by an ultrasonication method with methanol and 
DMSO as solvents and their aqueous mixtures. Quantitative analysis of individual 
ginsenosides from the extracts were measured by HPLC. These results showed that 
ultrasonication significantly enhanced the extraction efficiency, with the best efficiency 
found using 80% solvent (methanol, and DMSO) and 20% water. A large amount of 6”-
O-acetylginsenoside Rb1 was found using ultrasonic extraction of North American 
ginseng with DMSO aqueous solution. This new ginsenoside was well identified with 
MS, FTIR, and 1D (1H and 13C) and 2D (gCOSY, gHSQC, and gHMBC) NMR. 
Subsequent bioassay experiments confirmed that acetyl ginsenoside Rb1 demonstrated 
additional immunosuppressive activity towards inhibiting the production of nitric oxide 
(NO) and tumor necrosis factor (TNF)-α in lipopolysaccharide (LPS)-induced 
macrophage cells in a dose-dependent manner using murine macrophages. In addition,  
using a human umbilical vein cell line, a strong anti-angiogenic effect was found, similar 
to ginsenoside Rb1. Due to this unique combination of pharmacological properties, this 
new ginsenoside is encouraging to be further explored for future development of novel 
drugs.  
34 
 
2.1 Introduction 
North American ginseng (Panax quinquefolius) is a medicinal plant used in traditional 
herbal medicines grown for its roots, similar to Asian ginseng (Panax ginseng C.A. 
Meyer), which also has a long history as a medicinal herb [1]. Native North Americans 
used the roots both as a health food [2] and as a traditional medicine for relieving fever, 
stomach ailments, etc [3, 4]. Ginseng extracts have demonstrated significant anti-stress, 
anti-angiogenic, immunosuppressive, and anti-oxidant activity [5-10]. The components 
isolated from North American ginseng and characterized include ginsenosides, 
polysaccharides, peptides, polyacetylenic alcohols, and fatty acids [11, 12]. The 
biological and pharmacological effects of ginseng are mainly attributed to the ginseng 
saponins, especially the class referred to as ginsenosides, with the structure of the six 
common ginsenosides displayed in Figure  2.1. In order to make use of these ginsenosides 
efficiently, it is necessary to separate them from ginseng root, identify them, and study 
their characteristic biological activities. Extraction is the first and most critical step in the 
separation of active ingredients from medicinal plants like ginseng. Not only are the 
ginseng extracts dependent on the genetic, growing and harvesting factors [13], they are 
also affected by the method of extraction and the utilized solvent [2, 14]. Different 
conventional extraction methods, such as Soxhlet extraction, reflux extraction, 
microwave-assisted extraction, and supercritical fluid extraction have been employed for 
extraction of ginsenosides from ginseng [3, 15, 16]. However, ginsenosides are thermally 
sensitive biologically active components they can be degraded to other ginsenosides at 
high temperatures [15, 17]. Degradation can be minimized by using the ultrasound 
assisted extraction technique. Ultrasonic extraction has been recognized for its simplicity 
and unique ability in the recovery and purification of active pharmaceutical ingredients 
from herbal plants providing higher efficiency, lower extraction times and lower solvent 
consumption [17-19]. Of additional benefit, the mechanical effects of acoustic cavitation 
from the inputted ultrasonic energy improves the diffusion of solvent into the plant tissue 
while also enhancing product release through the ruptured plant cell wall [14, 20, 21]. 
Wu et al. demonstrated that Asian and American ginseng extraction using ultrasonication 
with alcohols was approximately 3-times faster than conventional Soxhlet extraction 
[20]. Also, Liu et al. showed that higher content of malonyl ginsenosides, which are 
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thermally unstable and can degrade into corresponding neutral ginsenosides, were 
obtained using ultrasound assisted extraction with alcohols and water in comparison with 
other conventional techniques [16].  
Different ginsenosides isolated from various types of ginseng have different 
pharmacological effects. By using an in vitro survival assay, ginsenosides Rb1 and Rg1 
were found to protect spinal neurons from excitotoxicity induced by glutamate and kainic 
acid and oxidative stress induced by hydrogen peroxide, making them efficient 
neuroprotective agents for spinal cord neurons, while compound Re did not exhibit such 
activity [22]. It has been reported that isolated ginsenosides Rc and Rg1 showed an 
immunomodulatory effect on cellular immune response by stimulating T cell 
proliferation as well as NK cell activity [23]. Ginsenosides Rd, Re and Rg1 affected the 
immune system by enhancing specific-antibody responses [23]. Recently, it has been 
shown that ginsenoside Rg1 isolated from Korean ginseng partially supported 
immunomodulatory function and improved bone marrow suppression [24]. As the major 
ginsenoside component in North American ginseng, ginsenoside Rb1 demonstrated 
inhibition of proinflammatory cytokine responses for both lipopolysaccharide (LPS)-
induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α production in mice, but did 
not display the same patterns of inhibition as cell culture data [25, 26].  Ginsenoside Rb1  
also exhibited anti-angiogenic activity in-vivo [9], inhibiting the growth of new blood 
vessels and thus being used to treat cancer and age-related macular degeneration, etc. As 
an intestinal bacterial metabolite of ginsenoside Rb1, compound K (20-O-β-D-
glucopyranosyl-20(S)-protopanaxadiol, CK) has demonstrated immunosuppressive 
activity [10]. This activity could be utilized to prevent the body from rejecting an organ 
transplant, treating graft-versus-host disease after a bone marrow transplant, or for the 
treatment of auto-immune diseases. The other ginsenoside possessing this activity is 
ginsenoside Rh2, a biotransformation product of ginsenosides Rg1 and Rd [27]. Qi et al. 
reported that acetylation of protopanaxadiol ginsenosides could increase their anti-cancer 
activity [11]. Acetyl ginsenosides are expected to have higher bioactivity as the acetyl 
ginsenosides are more lipophilic and consequently may have a higher cellular uptake 
[28]. Gebhardt et al. acetylated ginsenoside Rb1  by means of lipase B of Candida 
antarctica, obtaining a mixture of 6”,6””-di-O-acetylginsenoside Rb1 (33%), 6”’’-O-
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acetylginsenoside Rb1 (60%) and 6”-O-acetylginsenoside Rb1 (7%) [28]. Wood et al. 
demonstrated that a significant amount of mono-acetate ginsenoside Rb1 could  be 
obtained using supercritical CO2 extraction with DMSO as co-solvent. However, they did 
not distinguish the type of mono-acetate compound [3]. Among the known ginsenosides, 
acetyl ginsenosides are normally reported as very minor components of the total 
ginsenoside content [29].  
 
 
Figure  2.1. Structure of common Panax quiquefolius ginsenosides [3]. 
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In the present study, ultrasonication extraction of ginseng was investigated using both 
pure solvents (methanol, DMSO) and their aqueous mixtures. The isolated high 
concentration of ginsenoside from North American ginseng extract is characterized for 
the first time to identify its molecular structure as 6”-O-acetylginsenoside Rb1, using 
mass spectroscopy, Fourier transform infrared spectroscopy (FTIR), and nuclear 
magnetic resonance (NMR). Also, the immunosuppressive and anti-angiogenic effects of 
the extracts and the isolated new ginsenoside were evaluated in-vitro using the murine 
macrophage and a vascular endothelial cell line, respectively, to determine the biological 
activity for its potential immunosuppressive and anti-angiogenic applications. 
 
2.2 Materials and methods 
2.2.1 Materials 
Roots of Panax quinquefolius came from Delhi, Ontario and collected by Dr. Dan Brown 
who is the leader for the Plant Biotechnology/Agriculture Platform Technology Group. A 
reference plant was deposited in Western University, Department of Biology Herbarium, 
entry number 52100. The dried root samples were ground in liquid nitrogen. Solvents 
(ethanol, methanol, acetonitrile, DMSO) of HPLC grade (>99.9%) were obtained from 
Sigma-Aldrich Canada. Purified water was produced from a Milli-Q water purification 
system (18.2 MΩ·cm resistivity, Barnstead EasyPureII, Thermo Scientific, USA). 
Ginsenosides Rg1, Re, Rb1, Rc, Rb2 and Rd were purchased from Indofine Chemical 
Company (Somerville, New Jersey, USA) and used as standards for HPLC analysis. 
Stock solutions were prepared in methanol at a concentration of 1000 µg/mL. Working 
standard solutions were prepared in methanol in the range 25-150 µg/mL for 
ginsenosides and then stored at -20°C. RAW 264.7 (ATCC TIB 67) murine macrophage 
cell lines and human umbilical vein cell lines (EA.hy926) were provided by Dr. Jeff 
Dixon (Department of Physiology and Pharmacology, Western University, Canada). BD 
OptEIA ELISA kits tumour necrosis factor-α were provided by BD Biosciences 
(Bedford, MA, USA). LPS (Lipopolysaccharides) from Escherichia coli and Griess 
reagent were purchased from Sigma-Aldrich (USA). Trypsin-EDTA was supplied by 
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Cellgro (Mediatech, Inc, Manassas, VA). Standard matrigel was provided by BD 
Bioscience (Bedford, MA, USA). Cell culture medium and reagents were purchased from 
Gibco laboratories (USA). 
2.2.2 General experimental procedures 
Ginsenoside concentrations were determined by a Shimadzu HPLC (Shimadzu 
Corporation) with an LC-20AB gradient pump, an SIL-20AC autosampler, and an SPD-
20A UV-Vis detector based on calibration with the ginsenoside standards. The column 
was an end-capped Luna 3u PFP (2) (Phenomenex Inc, USA) 100A of 150 × 4.60 mm 
with 5µm packing, kept at room temperature. The mobile phase, modified from [30], was 
a binary gradient of acetonitrile (A) and HPLC grade filtered water (B) at a constant 
composition of 21% A from 0–20 min followed by a linear gradient to 42% from 20–40 
min. The column was flushed and equilibrated after each analysis. The flow rate was 1 
mL/min, and the ginsenosides peaks were detected by a UV detector at 203 nm. For the 
analysis, 10 µL of the sample solution was injected from the HPLC vial onto the column. 
Unknown ginsenoside was collected manually using a Shimadzu HPLC (Shimadzu 
Corporation) with the same system as the analytical HPLC analysis using a semi-
preparative Atlantis T3 Waters column (250 × 10 mm with 5µm packing) kept at room 
temperature with purity of >99% (Appendix A). A full loop injection was employed (100 
µL) with the flow rate set at 4 mL/min and the unknown ginsenoside peak was detected 
by a UV detector at 203 nm. Data were collected using a Shimadzu class VP 7.4 SP3 
HPLC system software. All samples were filtered through 13 mm, 0.2 µm PTFE filters 
(Canadian Life Science, Peterborough, ON) attached to disposable 3 mL syringes prior to 
injection. In the case of semi-preparative analysis, the mobile phase was a binary gradient 
of acetonitrile (A) and HPLC grade filtered water (B) at a constant composition of 35% 
(A) for 2 min followed by a linear gradient to 50% from 2–30 min. The column was 
flushed and equilibrated for 35 min after each analysis. Fractions obtained were 
evaporated under vacuum to isolate the unknown extract. Semi-preparative HPLC assays 
were performed in duplicate. Molecular weight identification of ginsenoside Rb1 and 
unknown ginsenoside were obtained by mass spectrometry on a QTof Micro mass 
spectrometer (Waters) equipped with a Z-spray source and run in negative ion mode. 
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Mass survey data range between 200-1800 amu was recorded with a 3.2 kV capillary 
voltage and a 50 V cone voltage. Melting points were measured with a DSC Q200 (TA 
Instrument, New Castle, Delaware, USA). The scanning rate was 10 oC /min, with a 
scanning temperature range of 25–250 oC. FTIR-ATR (Nicolet 6700, Thermo Scientific) 
was used to investigate the chemical structure of the unknown ginsenoside
 
in the range of 
500-4000 cm-1. Moreover, NMR spectra were measured using either a Varian INOVA 
600 or a Varian INOVA 400 spectrometer at 25oC. Pyridine-d5 was used as the solvent 
and chemical shifts were referenced to tetramethyl silane (TMS; 0.0 ppm). 
2.2.3 Extraction and isolation 
Ginseng samples (100 mg) were placed in 20 mL sample vials and mixed with extracting 
solvent (DMSO and  methanol and their aqueous solution), with the mixture sonicated for 
30 min in a sonicating bath (VWR scientific products model 50D). This bath has a 
frequency of 35 kHz with the extraction temperature set initially at 25°C, with a 
maximum rise to no higher than 33°C. After extraction, the samples were centrifuged at 
4500 rpm for 10 min. The supernatant was subsequently collected with the residue 
washed with solvent and the procedure repeated twice, resulting in three collected 
samples which were then combined and evaporated to dryness under vacuum at 40°C. 
For each sample, three to four replicates were performed for statistical validation. DMSO 
being a high boiling point solvent (Tb=189°C versus 65°C for methanol) required vacuum 
drying in the presence of a lower boiling co-solvent, ethanol [31]. The ginseng extract 
was then characterized using analytical HPLC with an unknown component obtained 
which showed a different retention volume in the HPLC chromatogram from those of the 
known ginsenosides including Rg1, Re, Rb1, Rc, Rb2 and Rd [3]. The unknown 
ginsenoside was collected using a semi-preparative HPLC column. 
Moreover, the conventional extraction method of boiling and refluxing the solvent in a 
Soxhlet extractor for 10 h was used for comparison with the ultrasonic extraction method. 
1g ginseng powder was placed in a cellulose thimble and 30 mL methanol as a solvent 
was allowed to come to its boiling point.  
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2.2.4 Immunosuppressive effect of North American ginseng extracts 
The mouse macrophage cell line RAW 264.7 was cultured in Dulbeccos Modified Eagle's 
Medium supplemented with 10% FBS, 25 mM HEPES, 2 mM Glutamine, 100 IU 
penicillin/mL and streptomycin 100 µg/mL. The cells were kept at 37°C in a humidified 
incubator with 5% CO2 and seeded in 96-well tissue culture plates at a density of 1.5× 
105 cells per well. The inhibitory effect of ginseng extracts inflammatory mediators 
profile in vitro was evaluated as previously described [32]. The LPS-stimulatory response 
was measured by incubating macrophages with 1 µg/mL lipopolysaccharide (LPS) for 24. 
To examine the inhibitory effects of ginseng extracts, 5-150 µg/mL of 80% DMSO 
extract and 80% methanol extract as well as ginsenoside Rb1 and acetyl ginsenoside Rb1 
were added to the macrophages with 2 hr prior to the addition of  LPS. In this study, 
dexamethasone (DEX) was used as a positive control for the suppression of LPS-induced 
stimulation of macrophages. Dexamethasone which is used as an anti-inflammatory 
agent, has been shown to inhibit the production of NO and TNF-α  in cells stimulated 
with LPS [10, 33-36]. The 24 hr cytokine production induced by LPS was determined by 
measuring NO and TNF-α levels in the culture medium. TNF-α concentrations in 
supernatants from cultured cells were analyzed with ELISA. Samples were assessed with 
mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, USA) according to 
the manufacturer's protocol. Sample nitrite concentrations in culture medium were 
determined by means of Griess reagent (0.5% sulfanilic acid, 0.002% N-1-naphtyl-
ethylenediamine dihydrochloride, 14% glacial acetic acid). Culture supernatant of each 
sample and the Griess reagent (50 µL of each) were added to a 96 well plate. The 
measurements of absorbance were done at 550 nm wavelength using a Multiskan 
Spectrum microplate reader (Thermo Fisher Scientific, Finland) with SkanIt software 
(version 2.4.2, Thermo Fisher Scientific, Finland). Nitrite concentrations were calculated 
from a sodium nitrite standards calibration curve. 
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2.2.5 Anti-angiogenis effect of North American ginseng extracts 
Human umbilical vein cell lines (EA.hy926) were cultured in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with ECGS (20 mg/mL), 10% fetal bovine serum 
(FBS), 1% antibiotic, and 1 mL (5X) per 50 mL of medium Hat media supplement. The 
cells were grown at 37°C in humidified air with 5% CO2 incubator. When the cell 
cultures were 80%–90% confluent, cells were harvested following trypsin treatment and 
the released cells were resuspended to provide cell densities required for tube formation 
assays. To examine the anti-angiogenic activity of individual ginsenosides in vitro, 
human umbilical vein cell lines (EA.hy926) were seeded in 96 well tissue culture plates 
coated with matrigel at a density of 4.5 × 104 cells per well and incubated with medium 
and various concentrations of ginsenoside Rb1 and acetyl ginsenoside Rb1 (0.5-50 ppm) 
at 37°C for 20 hr. The images of tube formation were captured by an inverted microscope 
(Nikon TMS, Japan) using a 40x objective. Images from a total of five microscopic fields 
per well were analyzed by Motic Image Plus 2.0 software (Motic Instruments Inc., 
Richmond, Canada). The anti-angiogenic activities were estimated by counting the 
branch points of the formed tubes and the average numbers of branch points were 
calculated. Each experiment was repeated in triplicate. 
2.2.6 Statistical analysis 
All experiments were performed at least three times with statistical analysis 
accomplished using GraphPad prism 4.0a Software (GraphPad Software Inc., USA). Data 
was tested based on mean ± standard deviation (SD) of three sets of experiments. Data 
sets with multiple comparisons were evaluated by one-way analysis of variance 
(ANOVA) with Tukey’s and Dunnett’s post-hoc test. p < 0.05 was considered to be 
statistically significant. 
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2.3 Results and Discussion 
2.3.1 Identification of ginsenosides in North American ginseng 
extract 
North American ginsenosides extracted with the ultrasonic extraction method were 
analyzed by HPLC as shown in Figure  2.2, with excellent resolution of ginsenosides 
obtained (for Rb1, Rb2, Rc, Rd, Re and Rg1). By comparing the retention times of the 
ginsenosides in the extracts with known standards, peaks were identified as provided in 
Table  2.1. As shown in Table  2.1, by using the ultrasonic extraction method, the highest 
yield of ginsenosides was obtained using DMSO as solvent, giving a total ginsenoside 
yield of almost 10 (%, w/w). The results are comparable to literature where sonication 
extraction of powdered American and Asian ginseng roots and extracts in methanol 
showed a similar range of ginsenoside content (4.8 – 10.93 (%,w/w)) [21]. Also, the 
ginsenoside content (7.29 % w/w) obtained using the 10 h methanol Soxhlet extraction is 
consistent with previous studies on ginsenosides extraction from ginseng roots [3]. A 
substantial peak was detected in the ginsenoside region using this ambient temperature 
ultrasonic approach that did not correspond to the ginsenoside standards (see Figure 
 2.2a&b at 29 min), particularly when using DMSO as the extraction solvent. This peak 
concentration was calculated as an average of all calibration curves studied as provided in 
Table  2.1.  
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Figure  2.2. HPLC analysis of North American ginsenoside extract: a) DMSO ultrasonic 
extraction; b) Methanol ultrasonic extraction.  
a) 
b) 
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Table  2.1. Ginsenosides content from extraction of North American ginseng.  
Method Solvent Rb1 Rb2 Rc Rd Re Rg1 Acetyl 
Rb1 
ginsenoside 
content 
10 h 
Soxhlet 
extraction 
Methanol 3.78 
(2.83) 
0.14 
(11.18) 
0.73 
(4.11) 
1.06 
(2.79) 
1.33 
(3.36) 
0.25 
(10.18) 
0 7.29    
(1.27) 
Ultrasonic 
extraction 
DMSO 3.58 
(3.09) 
0.12 
(32.99) 
0.92 
(7.27) 
1.11 
(3.47) 
2.32 
(33.33) 
0.28 
(27.15) 
2.22 
(5.29) 
10.55  
(2.07) 
Methanol 4.43 
(9.04) 
0.15 
(13.02) 
0.85 
(7.67) 
1.05 
(2.60) 
1.43 
(5.97) 
0.26 
(16.01) 
0.17 
(17.65) 
8.34    
(0.61) 
 All values in (%, w/w). All runs are average of at least three repeats. Values shown in 
parentheses are percent relative standard deviations. 
For determination of the chemical identity of this peak, MS was performed in negative 
ion mode. The MS spectrum at 29 min showed a peak at 1149.9 m/z which was subjected 
to CID fragmentation, with the obtained MS/MS spectrum shown in Figure  2.3. This 
MS/MS spectrum illustrates the [M−H]− ion at 1149.9 m/z and its major fragment ions. 
The m/z of the peak and its fragmentation pattern correspond to the previously observed 
peak from LC-MS/MS of ginseng extracted using supercritical CO2 + DMSO [3]. In the 
MS
 
spectrum of Figure  2.3, the facial loss of an acetyl group is evidenced by the major 
peak at 1107.97 m/z, with the sequential loss of an acetyl-hexose and hexose group also 
observed (to generate peaks at 945.84, 783.76, 621.63 and 459.4 amu respectively). The 
acetyl ginsenoside Rc and acetyl ginsenoside Rd were also determined in the LC-MS/MS 
of ultrasonic extracts although the quantity of these ginsenosides was below the detection 
limit of the UV detector used for HPLC analysis (Figure  2.4).  
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Figure  2.3. Mass spectrum of peak at m/z 1149.95 for [M−H]− ions of acetyl ginsenoside 
Rb1 eluted at 29 min from ultrasonic extraction with DMSO.  
 
 
DMSO, 20 ul dry 20ul 50% ACN 28-May-201020:43:21
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Figure  2.4. Mass spectrum of peak at a) m/z 1119.93 for [M−H]− ions of acetyl 
ginsenoside Rc eluted at 25 min and b) m/z 987.86 for [M−H]− ions of acetyl ginsenoside 
Rd eluted at 26 min from ultrasonic extraction with DMSO. 
It can be observed that DMSO was found to be the best solvent for both Re and the 
unstable acetyl ginsenoside Rb1, with acetyl ginsenoside Rb1 extraction efficiency more 
than 10 times higher compared to methanol. As well, more efficient extraction of acetyl 
ginsenoside Rb1 was found with DMSO ultrasonication 2.22 (%, w/w), compared to 
around 1.00 (%, w/w) using supercritical fluid extraction [3]. Acetyl ginsenosides are 
typically thought to make up a very small amount of conventional ginseng extracts; they 
are believed to be thermally unstable and may convert to neutral ginsenosides under 
normal extraction conditions e.g. hot water extraction which would be used in 
conventional tea preparation [28]. Our results showed that the Soxhlet extraction method 
with methanol yielded no significant quantity of acetyl ginsenoside Rb1 which is in good 
agreement with literature [3].
 
The ability of ultrasound assisted extraction of ginseng 
employed at ambient temperatures in this study (25-33°C) with DMSO as a solvent 
yielded high amounts of acetyl Rb1 in less than 2 hr. This is a major advantage over 
Gebhardt et al's method of enzymatic synthesis which requires pure Rb1 to be converted 
into mono- and di- acetyl ginsenosides Rb1 in a 4 hr reaction [28].  
 
m/z
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2.3.2 Identification of acetyl ginsenoside Rb1 in North American 
ginseng extract 
The root of North American ginseng was extracted using DMSO or methanol. These 
extracts were subjected to HPLC analysis to yield six common ginsenosides (Figure  2.1) 
as well as one unknown ginsenoside. In order to chemically identity this unknown 
component, mass spectroscopy, FTIR, and NMR were used for characterization of the 
isolated sample. Figure  2.5 compares the mass spectrum of the unknown fraction with 
that of the commercial ginsenoside, Rb1. While the ginsenoside Rb1 showed a significant 
peak at m/z 1107.72, the unknown fraction demonstrated a major peak at m/z 1149.66. 
The mass difference of m/z 41.94 may be attributed an acetyl group attached to the 
ginsenoside Rb1. As previously reported [37, 38] in the negative ion mass spectra, the 
ionization of ginsenosides resulted in strong deprotonated molecular ions [M−H]− 
accompanied by their corresponding adduct ions [M+Cl]−, which might occur from 
contamination of the ion source. Hence, the other two major peaks at m/z 1143.73 for 
ginsenoside Rb1 and m/z 1185.61 for the unknown sample might be attributed to the 
Figure adduct ions [M+Cl]− with a higher m/z of 36 than the [M−H]− ions. 
 
Figure  2.5. Mass spectra of: a) ginsenoside Rb1 and b) the isolated unknown fraction 
obtained by the semi preparative HPLC of North American ginseng extract analysed by 
TOF-MS-ES. 
m/z800 900 1000 1100 1200 1300 1400
%
0
100
%
0
100 1149.66
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The unknown component was then examined with FTIR. Figure  2.6 compares the FTIR 
spectra of ginsenoside Rb1, DMSO extract, and the isolated unknown fraction. According 
to the literature [39-41] major peaks around 3300 cm-1 are due to O-H vibrations. The 
peaks around 2900 cm-1 are assigned to C-H stretching and the peaks at 1650 cm-1 are 
attributed to the C=C alkene stretching. The peaks at ~1010 cm-1 are attributed to the 
vibrations of C-C-O or C-C-OH in ginsenosides. The unknown fraction (Figure  2.6c) 
showed all the peaks possessed by the commercial ginsenoside Rb1 (Figure  2.6a), with 
additional peaks at 1730 and 1248 cm-1, which are attributable to the C=O and C-O 
stretching vibrations of an acetic ester group, respectively. These two additional peaks 
were also observed in the spectrum of the DMSO extract (Figure  2.6b) which contained 
the unknown component, but their height was much lower than that of the isolated pure 
unknown component due to its low concentration in the extract. Along with the mass 
spectroscopic result, the FTIR result confirmed the identity of the unknown component to 
be acetylginsenoside Rb1. 
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Figure  2.6. FTIR spectra for a) ginsenoside Rb1, b) DMSO ginseng extract, and c) the 
isolated unknown fraction.
. 
As a widely-recognized tool in the determination of molecular identity and structure for 
natural products, NMR was employed in the characterization of the isolated 
acetylginsenoside Rb1. According to the 1D (1H and 13C) and 2D (gCOSY, gHSQC, and 
gHMBC) NMR measurements, the isolated acetylginsenoside Rb1 was found to be 6”-O-
acetylginsenoside Rb1, with its molecular structure provided in Figure  2.7. In order to 
obtain complete structural information about the acetylginsenoside Rb1, 1H and 13C NMR 
spectra of the acetylginsenoside Rb1 were measured and compared with those of a 
commercial ginsenoside Rb1 sample. A comparison of the 1H NMR spectra of the 
extracted acetylginsenoside Rb1 and the commercial ginsenoside Rb1 is shown in Figure 
 2.8. 
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Figure  2.7. Proposed molecular structure of the extracted 6”-O-acetylginsenoside Rb1. 
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Figure  2.8. 1H NMR spectra of commercial ginsenoside Rb1 (bottom, blue) and the 
extracted acetylginsenoside Rb1 (top, red) in pyridine-d5. 
A few 1H peaks of the acetylginsenoside Rb1 are different from those of the commercial 
ginsenoside Rb1, including the C1” proton shifting from 5.38 to 5.33 ppm, the C3” proton 
shifting from 4.35 to 4.29 ppm, the C4” proton shifting from 4.36 to 4.15 ppm, the C5” 
proton shifting from 3.95 to 4.03 ppm, and the C6” protons shifting from 4.36 to 4.82, 
and 4.50 to 4.96 ppm. All these differences occur in the 2’-O-glucose unit, indicating that 
the acetyl group is attached to the C6” position. Moreover, a significant singlet at 2.05 
ppm (8”) in the spectrum of the acetylginsenoside Rb1 confirmed the presence of an 
acetyl group in the sample, which was absent in the spectrum of ginsenoside Rb1. Figure 
 2.9 compares the 13C NMR spectra of the extracted acetylginsenoside Rb1 and the 
commercial ginsenoside Rb1. 
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Figure  2.9. 13C NMR spectra of commercial ginsenoside Rb1 (bottom, blue) and the 
extracted acetylginsenoside Rb1 (top, red) in pyridine-d5.  
In addition to some minor differences, the major differences were found to be the C2’, 
C4”, and C6” carbon peaks shifting from 83.9 to 84.7 ppm, from 72.0 to 71.4 ppm, and 
from 63.1 to 65.1 ppm, respectively. With a close look at the spectra, the C5” carbon 
peak shifted from 78.7 to 75.7 ppm. Along with the additional acetyl peaks at 171.4 (7”) 
and 21.3 ppm (8”) in the spectrum of the extracted acetylginsenoside Rb1, these 
differences in the 13C peaks also provided evidence of the attachment of an acetyl group 
to the C6”. 
In addition to the 1D NMR measurements, the acetylginsenoside Rb1 was also examined 
with 2D (gCOSY, gHSQC, and gHMBC) NMR. The gHSQC and gHMBC spectra of the 
extracted acetylginsenoside Rb1 are displayed in Figure  2.10. In the gHSQC spectrum, the 
correlation peaks of C1”, C2”, C3”, C4”, C5”, C6”, and 8” are located at H5.33-C106.6, 
H4.13-C77.1, H4.29-C78.9, H4.15-C71.4, H4.03-C75.7, H4.82&4.96-C65.1, and H2.05-
C21.3, respectively. In the gHMBC spectrum of the extracted acetylginsenoside Rb1, the 
correlation peaks of H1”-C2’, H2”-C1”, and H8”-C7” can be clearly identified at H5.33-
C84.7, H4.13-C106.6, and H2.05-C171.4, respectively. All these results confirmed the 
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molecular structure of 6”-O-acetylginsenoside Rb1, with the 1H and 13C peaks of the 
commercial ginsenoside Rb1 and the extracted 6”-O-acetylginsenoside Rb1 being 
summarized in Table  2.2. 
 
Figure  2.10. gHSQC (top) and gHMBC (bottom) NMR spectra of the extracted 
acetylginsenoside Rb1 in pyridine-d5. 
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Table  2.2. Assignment of 1H and 13C NMR peaks of ginsenoside Rb1 and 6”-O-
acetylginsenoside Rb1 (in pyridine-d5). 
Position 
Commercial Ginsenoside Rb1 Extracted 6”-O-Acetylginsenoside Rb1 
1H Chemical Shift (ppm) 
13C Chemical 
Shift (ppm) 
1H Chemical Shift (ppm) 
13C Chemical 
Shift (ppm) 
1 0.74, 1.57 39.6 0.74, 1.56 39.6 
2 1.85, 2.21 27.2 1.85, 2.23 27.2 
3 3.28 (dd, J=11.52, 4.1 Hz) 89.3 3.28 (dd, J=11.65, 4.61 Hz) 89.6 
4 
 40.1  40.1 
5 0.67 56.8 0.72 56.8 
6 1.54 18.8 1.59 18.8 
7 1.21,1.47 35.5 1.20,1.48 35.5 
8 
 40.4  40.4 
9 1.37 50.6 1.40 50.6 
10 
 37.3  37.3 
11 1.57,1.97 31.2 1.57,1.99 31.2 
12 4.20 70.5 4.20 70.5 
13 2.00 49.9 2.01 49.9 
14 
 51.8  51.8 
15 1.02,1.57 31.1 0.98,1.57 31.1 
16 1.37,1.85 27.0 1.38,1.85 27.0 
17 2.60 52.0 2.60 52.0 
18 0.98 16.4 0.98 16.4 
19 0.83 16.6 0.85 16.6 
20 
 83.8  83.8 
21 1.67 22.8 1.67 22.8 
22 1.85,2.41 36.6 1.83,2.40 36.6 
23 2.41,2.60 23.6 2.40,2.60 23.6 
24 5.33 126.3 5.33 126.3 
25 
 131.4  131.4 
26 1.62 26.2 1.61 26.2 
27 1.67 18.3 1.67 18.3 
28 1.30 28.5 1.34 28.4 
29 1.12 17.0 1.14 16.8 
30 0.98 17.8 0.98 17.8 
3-O-glc-1’ 4.93 (d, J=7.42 Hz) 105.5 4.93 (d, J=7.91 Hz) 105.3 
2’ 4.26 83.9 4.16 84.7 
3’ 4.24 78.6 4.22 78.8 
4’ 4.16 72.0 4.15 71.8 
5’ 3.95 78.3 3.94 78.3 
6’ 4.36,4.58 63.3 4.37,4.57 (dd, J=11.87, 2.2 Hz) 63.2 
2’-O-glc-1” 5.38 (d, J=7.42 Hz) 106.5 5.33 106.6 
2” 4.14 77.5 4.13 77.1 
3” 4.35 78.8 4.29 78.9 
4” 4.36 72.0 4.15 71.4 
5” 3.95 78.7 4.03 75.7 
6” 4.36,4.50 63.1 4.82 (dd, J=11.43, 4.83 Hz), 4.96 (dd, J=11.87, 1.76 Hz) 65.1 
7” 
   171.4 
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(CH3COO) 
8” 
(CH3COO)   2.05 21.3 
20-O-glc-1’” 5.14 (d, J=7.81 Hz) 98.5 5.15 (d, J=7.47 Hz) 98.5 
2’” 3.93 75.2 3.94 75.2 
3’” 4.17 79.6 4.17 79.6 
4’” 4.24 72.1 4.24 72.1 
5’” 4.07 77.4 4.07 77.4 
6’” 4.33, 4.74 70.6 4.33, 4.75 70.6 
6’”-O-glc-1”” 5.11 (d, J=7.42 Hz) 105.7 5.12 (d, J=7.91Hz) 105.7 
2”” 4.06 75.6 4.05 75.6 
3”” 4.24 78.5 4.22 78.5 
4”” 4.07 72.0 4.07 72.0 
5”” 3.95 78.7 3.94 78.7 
6”” 4.34,4.53 63.2 4.35, 4.54 (dd, J=11.65, 2.42 Hz) 63.2 
 
Previously, Gebhardt et al. [28] synthesized 6”-O-acetylginsenoside Rb1 by means of an 
enzyme-catalyzed reaction of ginsenoside Rb1. However, 6”-O-acetylginsenoside Rb1 
was the minor product in comparison to the major products of 6”’’-O-acetylginsenoside 
Rb1 and 6”,6””-di-O-acetylginsenoside Rb1, indicating difficulties in obtaining a large 
amount of 6”-O-acetylginsenoside Rb1 using this strategy. We obtained pure 6”-O-
acetylginsenoside Rb1 using ultrasonic extraction of North American ginseng root 
without the need of separation of the mono- and di- acetylginsenoside Rb1. This method 
should be considered as an efficient and green approach, and thus preferred for obtaining 
6”-O-acetylginsenoside Rb1.   
2.3.3 Effect of solvents on the yields of ginsenosides 
It is known that different solvents will yield varying amounts and compositions of 
extract. The effect of extracting solvents can be seen in Table  2.1. The results show that 
DMSO is a good solvent for extraction of ginsenosides Rg1, Re, Rc, Rd, and specially 
acetyl Rb1 whereas methanol is a good choice for extraction of Rb1 and Rb2. According to 
the literature [32], to study the biological activity of ginseng extracts, usually 70-75% 
vsolvent/vwater has been used for ginseng extraction. Therefore, for studying the effect of 
adding water to the extraction solvent, a series of different solvent/water ratios (60-100% 
vsolvent/vwater) were examined on the extraction of ginsenosides from North American 
ginseng. Figure  2.11 compares the different solvent:water ratios for ginsenoside 
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extraction with DMSO and methanol solvents. The results show that using aqueous 
solvent mixtures of both methanol and DMSO solvents in the ultrasonic extraction of 
ginseng has a small effect on the yield of ginsenosides Rb2, Rc, Rd, Rg1, and acetyl Rb1. 
However, changing the solvent/water ratios (60-100% vsolvent/vwater) has a significant 
effect on the ginsenoside Rb1 yield which is the major and bioactive component of 
American ginseng. The highest extraction efficiency was obtained for most of the  
ginsenosides when using 80% solvent: 20% water. Therefore, in this study, 80% DMSO 
and 80% methanol extracts were employed in examining the biological activity of North 
American ginseng. 
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Figure  2.11. Comparison of different solvent: water ratios for ginsenoside extraction. a) 
DMSO:water ratios, b) Methanol:water ratios.   All runs are average of at least three 
repeats. 
The higher amount of acetyl ginsenoside Rb1 in ginseng extracts obtained with 
ultrasonication using DMSO at ambient temperatures (25-33°C) compared to methanol is 
potentially due to the higher solubility parameter of DMSO. The individual components 
of the solubility parameters of the solvents used in this study are shown in Table  2.3, 
which provides us with information on why the acetyl ginsenoside Rb1 could be 
selectively obtained when using DMSO as solvent. As shown in Table  2.3, compared to 
methanol, DMSO has a higher dispersion, orientation, and induction values which would 
enhance the solubility and stability of the acetyl ginsenoside Rb1. The Lewis acid–base 
interactions of DMSO's sulfonyl group with the carbonyl groups of acetyl ginsenoside 
could also enhance the stability of the acetyl ginsenoside. Moreover, DMSO has a zero 
acidity value which enables it to act as a proton acceptor for accepting hydrogen bonding 
that can lead to high solubility of acetyl compounds in DMSO. It has been reported that 
the solute-DMSO hydrogen bonding interaction is related to the proximity of the DMSO 
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molecule to the solute [42, 43]. For instance, as can be seen in Figure  2.12, the hydrogen 
bonding may happen when the oxygen atom of a DMSO molecule position is close to the 
hydrogen atom of the methyl group of acetyl ginsenoside Rb1. Also, secondary hydrogen 
bonding may occur between the hydrogen atom of the methyl group of DMSO and the 
oxygen atom of the carbonyl group of the acetyl ginsenoside Rb1. Poopari et al. studied 
different solvation models such as vibrational absorption (VA) in combination with 
density functional theory (DFT) calculations for testing the ester compound, methyl 
mandalate, solubility. They simulated this compound's solubility in organic solvents such 
as methanol, DMSO, and chloroform and showed that the solubility of methyl mandalate 
is related to the solvent–solute hydrogen-bonding interactions as well as the compounds 
structure. Therefore, future investigation is required to calculate the intermolecular 
hydrogen bond lengths between the acetyl ginsenoside Rb1 and the solvents which is a 
complex phenomenon.  
Table  2.3. The solubility parameters of solvents used in this study [44]. 
 
δd     
MPa1/2 
δo     
MPa1/2 
δi      
MPa1/2 
δa      
MPa1/2 
δb     
MPa1/2 
δt      
MPa1/2 
DMSO 17.2 12.5 4.3 0 10.6 24.5 
Methanol 12.7 10 1 17 17 29.7 
δd the dispersion forces, δo the orientation forces, δi  the induction forces, δa the acidity and δb the 
basicity, δt the total hilderbrand solubility parameter. 
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Figure  2.12. Possible hydrogen bonding between acetyl ginsenoside Rb1 and DMSO. 
Sulfur atom is yellow, oxygens are red, carbons are gray and hydrogens are white.  
2.3.4 Effect of North American ginseng extracts on LPS-stimulated 
production of NO and TNF-α in macrophages in vitro 
Although the effect of Panax ginseng and the isolated ginsenosides such as ginsenosides 
Rc, Re and Rg1 on the immune system for controlling inflammatory diseases and 
microbial infections has been studied extensively [23, 24, 45], there has not been many 
reports on the immunomodulation effects of North American ginsenosides. Therefore, it 
was decided to investigate whether or not acetyl ginsenoside Rb1 isolated from North 
American ginseng would possess immunomodulation effects. Although the 80% DMSO 
extract and the 80% methanol extract examined in this study did not show 
immunostimulatory activity (Figure  2.13), they demonstrated varying degrees of 
suppression of LPS stimulation of macrophages (Figure  2.14).  
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Figure  2.13. Immuno-stimulatory effects of 80% DMSO ginseng extracts (first row), 
80% methanol ginseng extracts (second row) on 24 hours macrophage production of NO 
(a,b), TNF-α (c,d). Murine macrophages (RAW 264.7 cells) were treated with or without 
ginseng extracts and LPS (1 µg/ ml) for 24 hours and the culture supernatants were 
analysed for NO and TNF-α by Griess reaction assay and ELISA respectively. Three 
independent experiments were performed and the data were shown as mean ± SD. 
Figure  2.14a&b display a significant inhibition of the production of NO and TNF-α in 
LPS-induced RAW 264.7 macrophages by the 80% DMSO ginseng extracts. This 
inhibition occurred in a dose-dependent manner within the dose range of 5-150 µg/mL 
extract, with a higher dose resulting in better inhibition. The 80% methanol ginseng 
extracts showed similar inhibitory effects, in spite of a relatively lower effect than that 
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using the DMSO ginseng extract (Figure  2.14c&d). With 5 µM of NO production being 
observed in the presence of 150 µg/mL DMSO extract, the more significant inhibition 
effect of this extract on NO production compared to the methanol extract could be due to 
the higher concentration of 6”-O-acetylginsenoside Rb1 in the DMSO ginseng extract. In 
order to investigate this hypothesis, the immunosuppressive activity of both the isolated 
6”-O-acetylginsenoside Rb1 and commercial Rb1 were examined by bioassay analysis 
using macrophages in-vitro. The 6”-O-acetylginsenoside Rb1 was isolated by prep HPLC. 
While ginsenoside Rb1 did not show any inhibitory effect on LPS-stimulation of 
macrophages (Figure  2.14e&f), which validated previous findings [10], 6”-O-
acetylginsenoside Rb1 significantly inhibited the production of NO and TNF-α in LPS-
induced RAW 264.7 macrophage cells in a dose-dependent manner within the dose range 
of 5-150 µg/mL (Figure  2.14g&h). Therefore, 6”-O-acetylginsenoside Rb1 isolated from 
North American ginseng significantly enhanced the immunosuppressive potency. It 
should be noted that transformed ginsenosides and ginsenoside metabolites have shown 
more potency toward cytotoxic activity than neutral ginsenosides [46, 47]. For instance, 
when 20(S)-ginsenoside Rg3 was metabolized to 20(S)-ginsenoside Rh2 or 20(S)-
protopanaxdiol by human intestinal microflora, the cytotoxicity of ginsenosides against 
tumor cell lines was enhanced [46]. Also, Ke-Ke et al. [48] isolated and identified four 
new ginsenosides from Panax ginseng and investigated their cytotoxicity against HL-60 
cells in vitro which showed medium and minor cytotoxicity. Therefore, the cytotoxicity 
of 6”-O-acetylginsenoside Rb1 should be  further evaluated. 
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Figure  2.14. Inhibitory effect of 80% DMSO ginseng extracts (first row), 80% methanol 
ginseng extracts (second row), ginsenoside Rb1 (third row), and 6”-O-acetylginsenoside 
Rb1 (fourth row) on LPS-stimulated 24hr macrophage production of  NO (a, c, e, g)  and  
TNF-α (b, d, f, h). Murine macrophages (RAW 264.7 cells) were pre-treated with the 
ginseng extracts and dexamethasone (5 µM)  for two hours after which LPS (1 µg/mL) 
was added, and the culture supernatants were analyzed for NO and TNF-α by Griess 
reaction assay and ELISA, respectively after 24 h. Dexamethasone (DEX) at 5 µM was 
used as a positive control. Three independent experiments were performed and the data 
were shown as mean ± SD. Datasets were evaluated by ANOVA. #Values p<0.05 
Significantly different from LPS-induced group. 
2.3.5 Anti-angiogenesis effect of North American ginseng extracts 
Ginsenosides are known to have paradoxical effects on angiogensis. Ginsenosides Rb1 
and Rg1 are known to possess anti and pro-angiogenic effects, respectively; however the 
structure-activity relationship is poorly understood [9]. To understand the anti-angiogenic 
effect of the isolated 6”-O-acetylginsenoside Rb1, this material was tested and compared 
with that of the commercial ginsenoside Rb1. As shown in Figure  2.15, under the 
influence of matrigel, a tube like network is observed in the control experiment. 
However, the magnitude of tubulization was reduced in the presence of either 
ginsenoside Rb1 or 6”-O-acetylginsenoside Rb1. The reduction of tube formation 
increased with increasing  treatment concentration dosage from 0.5 to 50 µg/mL. By 
comparing the anti-angiogenic effect of the two ginsenosides, it was found that both the 
6”-O-acetylginsenoside Rb1 and the commercial ginsenoside Rb1 showed similar anti-
6”-O-acetylginsenoside Rb1  
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angiogenic activity and exhibited similar potency towards inhibiting tube-like structure 
formation of endothelial cells. This finding is in agreement with a previous report by Qi 
et al. which showed that acetylation of protopanaxadiol ginsenosides could increase their 
anti-cancer activity [49]. Acetyl ginsenosides are expected to have higher bioactivity as 
the acetyl ginsenosides are more lipophilic and consequently may have a higher cellular 
uptake [50].  
Figure  2.15. Anti-angiogenesis activity of ginsenoside Rb1 and mono-o-acetylated 
ginsenoside Rb1. bottom panel, data represent the mean ± SD of the number of branch 
points relative to the control, which was set to 100%, counted in 10 microscopic fields of 
three independent experiments. #Values p<0.05 compared to control were determined to 
be significant. 
2.4 Conclusions 
In conclusion, ultrasonication extraction with DMSO and methanol as solvents at 
temperatures 25-33°C were investigated on North American ginseng powdered root. It 
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was successfully shown that DMSO and methanol were both effective solvents for 
ultrasonic extraction of ginsenosides, with DMSO in particular showing higher extraction 
and better selectivity. Aqueous solvents were found to increase the extraction efficiency 
in comparison with the pure solvents, with the best extraction efficiency obtained using 
80/20 vsolvent/vwater. Large quantities of 6”-O-acetylginsenoside Rb1 were found using 
ultrasonic extraction with DMSO which was fractionated and isolated using a preparative 
HPLC column and subsequently identified by MS, FTIR, and NMR. This study was the 
first to examine DMSO extracts, and 6”-O-acetylginsenoside Rb1 exhibiting significant 
potency towards inhibiting the NO and TNF-α production in LPS-induced macrophage 
cells in a dose dependent manner. 6”-O-acetylginsenoside Rb1 was shown for the first 
time to have an immunosuppressive effect, attributed to existence of the acetyl group, 
compared with ginsenoside Rb1, which did not show any immunosuppressive activity. 
Both ginsenoside Rb1 and 6”-O-acetylginsenoside Rb1 were shown to have similar anti-
angiogenic properties, suggesting that the presence of a aceylated moiety did not modify 
this biological effect.  
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Chapter 3  
 
 
3 Supercritical Fluid Chromatography of North 
American Ginseng Extract 
 
Abstract 
Supercritical fluid chromatography (SFC) using supercritical carbon dioxide (scCO2) is 
considered as a “green” separation method, particularly suitable for the isolation of 
thermally unstable bioactive components. However, co-solvent and additives are often 
required in the mobile phase due to the poor solubility of polar components in  scCO2. In 
the present study, the effect of temperature and pressure on the separation of ginsenosides 
was studied with methanol being added to the CO2 mobile phase. Acidic, basic, and ionic 
additives were introduced to the mobile phase, respectively, to study their effect on the 
separation of ginsenosides. The best separation conditions were achieved by adding 
trifluoroacetic acid in methanol (0.05% v/v) at 50°C and 150 bar. A high-concentration 
component in the extracts from the supercritical fluid extraction of North American 
ginseng was isolated by SFC and identified as sucrose using NMR, HPLC, and ESI-MS. 
These results show that SFC is a promising technique for the separation, isolation, and 
identification of ginseng extracts. 
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3.1 Introduction 
North American ginseng (Panax quinquefolius) is a medicinal plant used in traditional 
herbal medicines mainly grown for its roots, similar to Asian ginseng (Panax ginseng 
C.A. Meyer), which also has a long history as a medicinal herb [1]. Native North 
Americans used the roots of ginseng both as a health food [2] and as a traditional 
medicine for relieving fever, stomach ailments, etc [3, 4]. The components isolated and 
characterized in North American ginseng include ginsenosides, polysaccharides, 
peptides, polyacetylenic alcohols, and fatty acids [5, 6]. The most active ingredient of 
North American ginseng are known as ginsenosides which are polar triterpenoid saponins 
(Figure  3.1) and have been shown to provide valuable health effects including anti-
inflammatory, anti-stress, and anti-cancer properties [7, 8]. However, due to the thermal 
instability of some ginsenosides, the yield and quality of these extracts in North 
American ginseng are dependent on the extraction method [4]. 
Conventional extraction methods for ginsenoside isolation from ginseng include Soxhlet, 
ultrasound assisted extraction, and microwave assisted extraction [9-11]. Some of the 
conventional extraction methods require long extraction times and a larger amount of 
solvent, and may result in the thermal decomposition of the target components. 
Moreover, a subsequent filtration and/or concentration step is often required to remove 
the solid residue [9]. Supercritical fluid extraction (SFE) using CO2 and polar modifier 
has shown significant advantages in the extraction of medicinal plants [4, 12-15]. 
Previously we reported the isolation of ginsenosides and essential oils from North 
American ginseng using SFE [4]. Generally, ginsenosides are separated and analyzed by 
high performance liquid chromatography (HPLC) using water or organic solvents such as 
methanol and acetonitrile as mobile phases [4]. The SFE technique requires less 
separation time, and smaller amount of solvents, being considered as a “green” 
methodology [9]. In addition, better selectivity in the extraction of bioactive components 
has been obtained using the SFE approach [4]. The concentration step could be 
eliminated in SFE by simply lowering the density of supercritical fluids with reduced 
pressure. Moreover, the low critical temperature of CO2 makes this method very suitable 
for the extraction of thermally unstable compounds [9]. 
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Figure  3.1. Chemical structures of six common North American ginsenosides [4]. 
However, as medicinal and natural plants always consist of a variety of complex 
phytochemical ingredients, SFE cannot be used for the isolation of individual 
components from the extraction mixture. Different ginsenosides have been reported to 
have various biological and medicinal activities such as the diverse effects of Rb1 and 
Rg1 on the central nervous system and the unique anti-cancer effect of Rg3 [6]. Hence, 
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pharmacological studies require pure individual ginsenoside components. Therefore, the 
preparative chromatography systems based on supercritical fluids provide an interesting 
approach to separate and isolate the most precious components of medicinal plant 
extracts [16]. 
Possessing the advantages of SFE, supercritical fluid chromatography (SFC) is an 
attractive separation method with better selectivity and shorter analysis time due to the 
low viscosity, high diffusivity, and high solvating power of supercritical fluids compared 
to the traditional gas chromatography and high performance liquid chromatography 
(HPLC) [17, 18]. Under regularly used chromatographic conditions such as 100-120 bar 
pressure and 40°C temperature, the mobile phase fluid is not in the supercritical state, 
although SFC researchers use the terminology of SFC despite the state of the fluid 
employed [19]. Moreover, in a preparative SFC system, the desired material fractions are 
isolated in the dry form, removing most of the solvent residue by simply venting CO2. 
Therefore, SFC is a promising approach for separation and isolation of both 
pharmaceutical and nutraceutical active ingredients. Analytical and preparative SFC has 
been utilized  to isolate valuable components such as lipids, vitamins and other bioactive 
compounds from extracts [16-18, 20-22]. The only application of SFC reported in the 
separation of ginsenosides was from Asian ginseng extracts by Li et al. [23]. In that 
study, pure CO2 was used as the mobile phase with pressure gradient from 100 to 350 bar 
and temperature at 300°C to separate panaxadiol and panaxatriol which are the acid-
hydrolyzed products of ginseng. As pure CO2 has a low solvation power for polar 
components, the individual ginsenosides could not be selectively separated. For 
separation and isolation of polar components such as ginsenosides, organic polar 
modifiers are often required to add to the CO2 mobile phase to increase the solvating 
power of the mobile phase [24].  
In the present study, we examine the SFC of both individual ginsensosides and mixtures 
of ginsensosides at various temperatures and pressures while examining several typically 
used additives. We previously reported that DMSO was a useful co-solvent in SFE of 
North American ginseng, extracting unusual lipophillic ginsenosides (mono-acetylated 
Rb1s) which may have higher biological activity [4]. We hypothesized that better 
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separation of ginsenosides could be achieved by adding polar organic solvents such as 
methanol. Hence, we then examined the isolation and identification of individual 
ginsenosides in the SFE extracts of North American ginseng by SFC. The effect of a 
small amount of polar additives such as acid, base, and aqueous ionic solution on the 
separation of ginsenosides are examined in this work. An unknown high-concentration 
component in the SFE extracts of North American ginseng was also found,  characterized 
and identified.  
 
3.2 Materials and methods 
3.2.1 Materials 
Ground, dried, root of North American ginseng was obtained from Agriculture and Agri-
Food Canada. The volume weighted mean diameter of the powder was found as 550 µm, 
as determined by dynamic light scattering (Hydro 2000MU Malvern Instruments Ltd,.). 
Solvents (ethanol, methanol, and DMSO) of HPLC grade (>99.9%), ammonium acetate 
(99%, ACS grade), trifluoroacetic acid (TFA) (99%), and diisopropylamine (DIPA) 
(99%) were obtained from Sigma-Aldrich Canada. The carbon dioxide SFC grade was 
purchased from Praxair, Inc., USA. Purified water was produced from a Milli-Q water 
purification system (18.2 MΩ·cm resistivity, Barnstead EasyPureII, Thermo Scientific, 
USA). Ginsenosides Rg1, Re, Rb1, Rc, Rb2 and Rd were provided by Dr. Ed Lui's lab 
(Department of Physiology and Pharmacology, Western University, Canada) and used as 
standards for SFC analysis. Stock solutions were prepared in methanol at a concentration 
of 1000 µg.ml-1 and then stored at -20°C. 
3.2.2 Ginseng supercritical extracts preparation 
An Isco SFE unit was employed for North American ginseng extract preparation as 
previously described  [4]. Briefly, 1 g of ginseng root powder was mixed with 19 g of 
sand and then placed in a 10-mL extraction vial. 3.2 (g DMSO/g ginseng) was spread directly 
onto the solids, prior to placing them in the extraction vessel. The experimental 
conditions were at a temperature of 110°C, and pressure of 34.5 MPa which were shown 
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to form a single phase with DMSO [4]. After 60-min extraction, a dynamic CO2 and 
DMSO as modifier was charged to the system to recover the extracted product in to 
ethanol as the trapping liquid. Extracted materials were evaporated under vacuum at 40°C 
and the total mass was weighted and kept at -20°C prior to supercritical fluid 
chromatography. All SFE experiments were done by triplicate. 
3.2.3 Supercritical fluid chromatography (SFC) of ginseng extracts 
The SFC unit used for all analytical and semi-preparative separations is a Thar SFC 
instrument (Pittsburgh, PA) including a fluid delivery module with high pressure pumps 
for CO2 and modifier delivery, a column oven for temperature control, autosampler, 
automated back pressure regulator (ABPR) for column pressure controlling, and an UV-
Vis detector as well as an evaporate light scattering detector (ELSD) (Polymer 
Laboratories Inc, MA, USA) with drift tube temperature at 80°C (Figure  3.2). 
 
 
Figure  3.2. Schematic of the supercritical fluid chromatography (SFC) system. (A) CO2 
cylinder; (B) filter; (C) cooler; (D) CO2 pump; (E) modifier reservoir; (F) modifier pump; 
(G) mixer; (H) sampler; (I) column and oven; (J) UV detector; (K) ELSD detector; (L) 
automated back pressure regulator (ABPR); (M) vent; (N) fraction collector. 
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In the present study, ELSD was considered as an ideal detection system due to low UV 
wavelength of ginsenosides which is around 203 nm. The SFC column used was a 
cyanopropyl packed column (250 × 4.6 mm, dp 5 µm, 60 Å) (Princeton Chromatography 
Inc., NJ, USA) which is a polar stationary phase. The SFC system includes six fraction 
collector vessels for sample fractionation. SFC conditions examined were pressures from 
100-200 bar, and temperatures from 32-50°C. Methanol was used as the modifier due to 
its high solubility in CO2 and high polarity and ability to disturb solute–plant matrix 
bonding [4]. The mobile phase (CO2:methanol ratio) flow rate was 1.5 mL/min. For the 
analysis, a partial loop (20 µL) of  sample solution was injected to the SFC system and 
the mobile phase gradient composition was as 15% modifier in CO2 for 1 min after 
injection followed by an increase in mobile phase concentration to 31% at rate of 2% per 
min, and was kept at 31% until the end of run. Additives were added into methanol as 
modifier (v/v) before mixing with CO2. To help achieve stable chromatographic 
conditions, the mobile phase went through the column for 30 min before sample 
injection. Also, prior to each change of mobile phase additive, the column was washed 
with pure methanol for at least one hour at 1 mL/min for preventing previous analyte 
column contamination. Then, for column equilibration, the mobile phase with the next 
additive was introduced to the system 30 min prior to sample injection. In order to collect 
sample fractions, a full loop (100 µL) of sample solution at 10 mg/mL was injected to the 
SFC system. Fractions collected in the SFC vessels were dried under vacuum at room 
temperature prior to further characterization.  
3.2.4 Analysis of supercritical fluid chromatography unknown 
fraction 
Several techniques were employed to identify the unknown isolated fraction including 
nuclear magnetic resonance (NMR), HPLC-RID, and electrospray ionization mass 
 spectrometry (ESI-MS). 1D (1H and 13C) and 2D (gCOSY, gHSQC, gHMBC) NMR 
spectra were measured using either a Varian INOVA 600 or a Varian INOVA 400 
spectrometer at 25oC. Methanol-d4 (CD3OD) was used as the solvent and chemical shifts 
were referenced to tetramethyl silane (TMS; 0.0 ppm). HPLC-RID system was used to 
identify the unknown semi-preparative SFC fraction. HPLC analysis was performed 
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using HPLC-RID system (Agilent Technologies Inc., USA) with a Hi-Plex H column 
(Zorbax, Agilent Technologies Inc., USA) 50 x 7.7 mm with 0.005 M sulfuric acid in 
water solution as mobile phase, at a temperature of 65°C isocratically and a flow rate of 
0.6 mL/min. Molecular weight identification of the unknown semi-preparative SFC peak 
was obtained by ESI-MS analysis on PE-Sciex API 365 triple quadrupole mass 
spectrometer with a mass range (m/z) of up to 3000 . 
 
3.3 Results and Discussion 
3.3.1 Supercritical fluid chromatography of North American 
ginsenosides 
Our preliminary results showed that pure CO2 was a poor mobile phase for separation of 
the polar components of North American ginseng extract, particularly for the ginsenoside 
components of interest. This is attributed to the low solubility of the polar ginsenosides in 
pure CO2; therefore methanol was added as a modifier in the SFC mobile phase. Isocratic 
methanol concentration (e.g. 5%, 15% and 31%) was first tested for the separation of a 
ginsenoside standards mixture (Appendix B). The results showed that 5% methanol in 
scCO2 caused co-elution and poor separation of all ginsenosides. The use of 15% 
methanol in scCO2 resulted in better separation of ginsenosides, with Rg1 and Re being 
eluted as a mixture. Using 31% methanol in scCO2 led to a better separation of the 
ginsenoside Rd, but gave poorer separation of the mixture of ginsenosides Rg1 and Re. 
Also, ginsenosides Rb1, Rb2 and Rc co-eluted with large tailing in the case of using 
isocratic methanol concentration (e.g. 15% and 31%). A higher concentration of modifier 
did not improve the peak shapes. However, a gradient composition of methanol in scCO2 
from 15-31% resulted in better peak shapes and symmetry of ginsenosides with no tailing 
and gave relatively good separation of ginsenoside Rd and partial separation of 
ginsenosides Rg1 and Re in the mixture. Therefore, for the purpose of better fractionation 
of ginsenosides, a gradient composition of methanol in CO2 was employed with the 
mobile phase consisting of 15% methanol in CO2 for 1 min after injection, then 
increasing the methanol concentration to 31% at a rate of 2% per minute and kept at 31% 
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until the end of run. In order to select an optimal condition for the SFC experiments, the 
effect of temperature and pressure on the retention time and peak shape of the 
ginsenosides standard was investigated first. The effect of temperature on the retention 
time was examined at three different temperatures, 32, 40 and 50°C under a constant 
pressure of 150 bar with a flow rate of 1.5 mL/min. In order to identify the valuable 
ginsenoside components, each of the six common ginsenosides standards (Figure  3.1) 
was injected in the SFC-ELSD system, with the retention times listed in Table  3.1. A 
mixture of the six ginsenosides standards was injected to examine the effect of 
temperature and pressure on the separation efficiency. As shown in Figure  3.3 and Table 
 3.1, the retention time of all the ginsenosides increased with increasing temperature in the 
range of 32-50°C. Also, it can be seen that at T=32°C, ginsenosides Rg1 and Re co-eluted 
within 7.8-8 min whereas ginsenosides Rd, Rc, Rb2, and Rb1 eluted within 9.3-9.8 min. 
By increasing temperature from 32°C to 40°C, better separation was obtained. At 
T=40°C, ginenoside Rd separated as an individual peak at 11.5 min, although 
ginsenosides Rb2, Rc, and Rb1 still eluted as one peak within the range of 11.8-12.3 min. 
At T=50°C, ginsenoside Rg1 and Re could be partially isolated while better isolation of 
ginsenoside Rd was achieved. It should be noted that the elution order of these 
ginsenosides did not change with increasing temperature from 32 to 50 oC except Rc at 
T=32 oC. Also from the separation point of view, our results show that at P=150 bar and 
T=50°C ginsenoside Rd was well separated from the panaxidoal ginsenosides (Rb1, Rb2, 
Rc) and the panaxitrol ginsenosides (Rg1, Re). However, when using lower separation 
temperatures (i.e. T=40°C and T=32°C), only partial separation was achieved. 
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Table  3.1. Retention time of individual ginsenoside standard at different temperatures 
under 150 bar, with 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 
mL/min. 
Ginsenoside Retention Time (min) 
T=32oC T=40oC T=50oC 
Rg1 7.8 10.5 12.5 
Re 8.0 11 12.7 
Rd 9.3 11.5 13.3 
Rb2 9.6 11.8 13.8 
Rc 9.4 12 14 
Rb1 9.8 12.3 14.2 
 
 
Figure  3.3. Effect of temperature on the retention time of ginsenoside standards mixture 
at 150 bar, with 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min. 
a) T=32 °C, b) T=40 °C, and c) T=50 °C. 
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In explanation, under a constant pressure, the density of the mobile phase decreased with 
increasing temperature, leading to a lower solvating power of the mobile phase. The 
lower solubility of the ginsenosides in the mobile phase resulted in longer retention times. 
This explanation was echoed during the study of the effect of pressure on the retention 
time. 
As shown in Figure  3.4 and Table  3.2, the retention time of all the ginsenosides decreased 
with increasing pressure from 100 to 200 bar at a constant temperature of 50°C. The 
increased pressure at constant temperature resulted in increased density and solving 
power of the mobile phase, leading to a shorter retention time. By investigating the 
pressure effect, at first the best separation seemed to be obtained at P=100 bar, however 
the peak shapes and the baseline were noisy which may be due to lower solubility of 
ginsenosides in the mobile phase under these conditions. At P=200 bar, ginsenosides Rg1 
and Re eluted as one peak whereas ginsenoside Rd was partly isolated from Rc, Rb2, and 
Rb1. By comparing the chromatographic profiles of the mixture of ginsenoside standards 
under these conditions, the best condition for the separation of ginsenosides was found to 
be T=50°C and P=150 bar. It should be noted that the elution order of ginsenosides Rb2 
and Rc was altered at P=100 bar and P=200 bar. Usually, the elution order in SFC is 
determined by the number of hydroxyl groups in the analyte. When a polar stationary 
phase is used, the retention time increases with increasing number of hydroxyl groups  in 
the analyte [25]. However, for ginsenoside Re with the same number of hydroxyl groups 
as Rd, the hydroxyl group on carbon 3 is very close to the two methyl groups on carbon 
4. Hence, the interactions between this hydroxyl group and the stationary phase could be 
reduced by steric hindrance. Therefore, ginsenoside Re eluted earlier than ginsenoside Rd 
[25]. 
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Table  3.2. Retention time of individual ginsenoside standard under different pressures at 
50°C, with 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min. 
Ginsenoside Retention Time (min) 
P=100 bar P=150 bar P=200 bar 
Rg1 12.8 12.4 11.2 
Re 13.4 12.6 11.3 
Rd 13.8 13.3 11.8 
Rb2 15.5 13.8 12.4 
Rc 15.2 14 12.2 
Rb1 15.8 14.2 12.6 
 
 
 
Figure  3.4. Effect of pressure on the retention time of ginsenosides standard mixture at 
50°C, with 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min. a) 
P=100 bar, b) P=150 bar, and c) P=200 bar. 
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3.3.2 Effect of additives on elution of North American ginsenosides 
As the utilized binary mobile phase (CO2/methanol) was not ideal in the separation of  
the standard ginsenoside mixture, we hypothesized that better separation could be 
achieved by adding additives to the mobile phase. Three different compounds including 
trifluoroacetic acid (TFA),  diisopropylamine (DIPA), and aqueous ammonium acetate 
solution were added to the CO2 mobile phase, respectively. These compounds represent 
three different types of additives, i.e., acidic, basic, and ionic additives, respectively. 
Figure  3.5 displays the chromatograms of the mixture of the ginsenosides standards by 
adding a small amount of TFA to the mobile phase (gradient 15-31% methanol in CO2) 
under the selected chromatographic conditions of temperature 50°C, pressure 150 bar, at 
a flow rate of 1.5 mL/min. According to the retention time of the individual ginsenoside 
standards, it was found that the elution of ginsenosides Rg1, Re, and Rd was improved 
with  0.05% v/v TFA being added to the mobile phase. The co-elution issue of 
ginsenoside Rg1 with Re was resolved, although ginsenoside Re and Rd eluted partially 
together. Hence, the separation efficiency of ginsenosides Rg1, Re, and Rd was improved. 
By increasing the percentage of TFA in the mobile phase from 0.05% v/v to 0.1% v/v, 
ginsenoside Re and Rd co-eluted within 11-12 min and no difference was observed for 
other ginsenosides elution. Therefore, 0.05% v/v TFA in the mobile phase seems to be 
the optimum acidic additive amount that is useful for isolation of ginsenosides. In 
addition, the retention times of the ginsenosides decreased slightly with increasing TFA 
concentration in methanol from 0.05% v/v to 0.1% v/v. This decrease in retention time 
may be attributed to the improved solvating power of the mobile phase due to the 
addition of the acidic additive [26]. TFA can potentially enhance separation of the 
ginsensosides by either protonation of their hydroxyl groups or protonating the 
unmodifed Si-OH groups on the separation column, leading to enhanced solvent/solute 
interactions [27]. 
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Figure  3.5. SFC-ELSD chromatogram of the mixture of ginsenosides standard at 50°C, 
150 bar, 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min with the 
addition of a) 0.0% of TFA; b) 0.05% TFA; c) 0.1% TFA. 
To investigate the effect of basic additive, 0.1%v/v and 0.5%v/v of DIPA was added to 
methanol and then introduced to the mobile phase. Under the chromatographic condition 
of temperature 50°C, pressure 150 bar, at a flow rate of 1.5 mL/min, the mixture of 
ginsenoside standard was injected to the SFC-ELSD system. The chromatograms with 
addition of DIPA are displayed in Figure  3.6. Based on the retention times of the 
ginsenosides standard under the same conditions, ginsenosides Rg1 and Re were better 
separated by adding 0.1% v/v of DIPA in methanol. However by increasing the 
concentration of DIPA from 0.1% v/v to 0.5% v/v in the mobile phase, further 
improvement was not observed for isolation of ginsenosides. Similarly, the introduction 
of 0.1% v/v of DIPA into methanol resulted in decreased retention times of the 
ginsenosides (Figure  3.6). This suggests that the interactions of DIPA with the utilized 
cyano SFC column increased, decreasing ginsensoside-column interactions. Further 
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increasing the amount of DIPA from 0.1%v/v and 0.5%v/v in methanol did not affect the 
retention times of the ginsenosides but led to poorer peak shape and separation of the 
ginsenosides, possibly due to partial phase separation.  
 
Figure  3.6. SFC-ELSD chromatogram of the mixture of ginsenosides standard at 50°C, 
150 bar, 15-31% methanol in CO2 at a flow rate of 1.5 mL/min with the addition of: a) 
0.0% DIPA; b) 0.1% DIPA; c) 0.5% DIPA. 
The effect of ionic additive on the SFC was evaluated by adding 10 mM of AA aqueous 
solution to the mobile phase. As shown in Figure  3.7, adding the ionic additive into the 
mobile phase gave no improvement on the separation of ginsenosides with ginsenoside 
Rg1 and Re being co-eluted with ginsenoside Rd. Increasing the amount of water to 5% 
v/v with 10 mM AA in methanol could not improve the ginsenoside elution and the 
baseline became noisy with poor signal/noise ratio. In contrast to the addition of TFA or 
DIPA, there was no significant change in the retention times of ginsenosides by adding 
86 
 
AA aqueous solution. Along with the poorer peak shape and separation with increased 
amount of AA aqueous solution, the introduction of ionic additive is believed to cause 
phase separation of the neutral ginsenosides in the mobile phase. 
 
Figure  3.7. SFC-ELSD chromatogram of the mixture of ginsenosides standard at 50°C, 
150 bar, 15-31% methanol in CO2 at a flow rate of 1.5 mL/min with addition of: a) no 
ionic additive; b) 3% v/v solution of 10 mM AA; c) 5% v/v solution of 10 mM AA. 
By comparing the addition of the three types of additives, under the same 
chromatographic conditions with the cyanopropyl stationary phase, the best peak shape, 
symmetry, efficiency, and resolution for mixture of ginsenoside standards was obtained 
by using the acidic additive TFA. In general, due to the presence of various site isomers 
on different carbon atoms, not all of North American ginsenosides could be isolated by 
SFC-ELSD under the studied conditions. These results are in good agreement with 
reports in the  literature under the same conditions and in the presence of additives where 
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hydrogen bond donor/acceptor analytes retention time were additive dependent [18, 24, 
28]. Therefore, in all cases the retention time of ginsenosides slightly decreased by 
increasing the additive concentration in the mobile phase. 
3.3.3 Supercritical fluid chromatography of North American 
ginseng extracts 
The extracts of North American ginseng was obtained with the SFE method using 
supercritical CO2 as described above. By employing a modifier DMSO, a total quantity 
of extracted material of 350 mg/g with a relative standard deviation of 3.21% based on 
three replicates was achieved. The extracts were subsequently fractionated by means of 
SFC-ELSD. The optimum chromatography conditions of 50°C, 150 bar, 15-31% 
methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min with the addition of 0.05% 
TFA performed for separation and isolation of ginsenosides from SFE North American 
ginseng extracts. According to the retention times of the ginsenoside standards under the 
same conditions, the peaks of the ginsenosides in the extracts were identified between 10 
and 13 min (Figure  3.8). As can be observed in Figure  3.8a, ginsenoside Rg1 separated 
within 10-11 min followed by ginsenoside Re, in addition ginsenoside Re and Rd isolated 
partially within 11.5-12.3 min. However, ginsenosides Rb2, Rc, and Rb1 in the SFE North 
American ginseng extract co-eluted within 12.4-13 min. Our results are consistent with 
the previous study [4] which showed that the main ginsenosides compound of  SFE North 
American ginseng extract is ginsenoside Rb1, and in a lower degree, ginsenosides Rd and 
Re. Ginsenosides Rc, Rg1, and Rb2 are present in North American ginseng extract in 
lower amounts, respectively. Figure  3.8b shows the SFC chromatograph of SFE North 
American ginseng extracts in optimum selected condition. Interestingly, an extensive 
peak was detected at 8 min that did not correspond to any of the ginsenoside standards 
(Figure  3.8b). As the literature contained no information on this observation, we decided 
to isolate and identify the unknown component. 
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Figure  3.8. SFC-ELSD chromatograph of a) SFE North American ginsenoside separation 
(enlargement of ginsenosides region); b) the SFE North American ginseng extracts at 
50°C, 150 bar, 15-31% methanol in CO2 as mobile phase at a flow rate of 1.5 mL/min 
with the addition of 0.05% TFA. 
3.3.4 Identification of the unknown component 
During the SFC separation of the SFE extracts of North American ginseng, an extensive 
peak was detected between 7-9 min, which was not attributed to any ginsenosides and has 
not been reported in any literature. Due to its high concentration in the SFE extracts, it 
was deemed necessary to identify this component. NMR, HPLC-RID, and ESI-MS were 
employed in the characterization of this component, which was fractionated by the semi-
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preparative SFC system at pressure 150 bar, temperature 50 °C, flow rate of 1.5 mL/min, 
mobile phase of CO2/methanol with a gradient composition of 15-31% at 2% per min. 
NMR is a powerful tool in identifying the chemical structure of an organic chemical. As 
shown in Figure  3.9, the 1H peaks appeared between 3.42 and 5.39 ppm in the 1H NMR 
spectrum while 12 distinct 13C peaks were present between 62.4 and 105.5 ppm in the 13C 
NMR spectrum (Figure  3.10). 
 
 
Figure  3.9. 1H NMR spectrum of the unknown fraction (in CD3OD). 
In order to understand the relationship among these 1H and 13C peaks, 2D NMR spectra 
of gCOSY, gHSQC, and gHMBC of the unknown fraction were also measured (Figure 
 3.11). By analyzing these 1D and 2D NMR spectra, the chemical structure of the 
unknown fraction was proposed in Figure  3.12, with the peaks being assigned and listed 
in Table  3.3. Interestingly, this structure is identical to the commonly known 
disaccharide, sucrose. 
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Figure  3.10. 13C NMR spectrum of the unknown fraction (in CD3OD). 
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Figure  3.11. 2D NMR spectra of gCOSY (top), gHSQC (middle), and gHMBC (bottom) 
of the unknown fraction (in CD3OD). 
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Figure  3.12. The proposed structure of the unknown fraction based on the 1D and 2D 
NMR spectra. 
Table  3.3. Assignment of the peaks in the 1H and 13C NMR spectra of sucrose (in 
CD3OD). 
 
No 1H Chemical Shift (ppm) 13C Chemical Shift (ppm) 
1 5.39d (J=3.66Hz) 93.8 
2 3.42dd (J1=9.52Hz, J2=3.66Hz) 73.4 
3 3.70 74.8 
4 3.36dd (J1=10.14Hz, J2=8.97Hz) 71.5 
5 3.81-3.84 74.6 
6 3.72-3.73,3.79-3.81 62.4 
7 3.62q (J=12.45Hz) 64.2 
8 n.a. 105.5 
9 4.09 79.5 
10 4.02t (J=8.06Hz) 75.9 
11 3.75-3.77 84.0 
12 3.75-3.77 63.5 
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The HPLC-RID chromatogram of the unknown fraction was collected and compared with 
that of a reference sample (commercial sucrose) in Figure  3.13. It should be pointed out 
that the presence of sulfuric acid in the mobile phase and the temperature of 65°C caused 
the commercial sucrose to be hydrolyzed to monosaccharides glucose and fructose [29]. 
Hence, two distinct peaks appeared in the chromatogram of the reference sample, at 
11.273 and 12.028 min, respectively (Figure  3.13a), with the former peak assigned to 
glucose and the latter one attributed to fructose. The chromatogram of the unknown 
fraction also showed two peaks at 11.284 and 12.039 min, respectively (Figure  3.13b), 
which are essentially at the same retention times as that of the reference sample. 
 
   
 
Figure  3.13. HPLC-RID chromatogram of a) sucrose standard; b) unknown fraction 
obtained by the preparative SFC of North American ginseng extract. 
In addition, the unknown fraction was also characterized with ESI-MS, with the mass 
spectrum being displayed in Figure  3.14. Due to the application of NaI as an external 
standard, Na+ was adducted to the sample molecule, showing a dominant peak at 
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365.1Da, which can be assigned to [sucrose+Na]+. Another quasimolecular ion, 
[sucrose2+Na]+ showed a peak at 707.2 Da (684+23). These results are in good agreement 
with the spectra of sucrose reported in the literature [30, 31]. 
 
Figure  3.14. Mass spectra of unknown fraction obtained by the preparative SFC of North 
American ginseng extract analysed by ESI-MS. 
Although the most biologically active ingredients of ginseng extracts are ginsenosides, 
ginseng extracts have been reported to consist of different components such as amino 
acids, fatty acids, carbohydrates, alkaloids, polysaccharides, sesquiterpenes, 
polyacetlyenes, peptidoglycans, minor elements, vitamins, and phenolic compounds [6]. 
In a recent report analyzing North American Ginseng by HPLC, Lui et al. [32] found 
glucose as the major monosaccharide at 77-86 % (w/w), galactose at 6.8-7.5 % (w/w), 
arabinose at 4.5-5.9 % (w/w), and galacturonic acid at 8.7- 9.5 % (w/w). This analysis did 
not report  finding sucrose although significant quantities of higher molecular weight 
bioactive carbohydrates were reported. Supercritical CO2 in combination with polar co-
solvents would increase the solubility of disaccharide. Montanez et al. found that 
different polar co-solvents such as isopropanol and ethanol and water mixtures were 
sucrose+Na+ 
sucrose2+Na+ 
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capable of enhancing solubility, selectivity, and yield for the fractionation of binary 
carbohydrate mixtures [33]. Hence in this work SFC was successfully employed in the 
separation of the SFE extracts of North American ginseng using supercritical CO2, co-
solvent, and appropriate additives, leading to fractionation of several ginsenosides and 
the disaccharide sucrose. 
 
3.4 Conclusions 
Supercritical fluid chromatography coupled with an evaporative light scattering detector 
was employed in the separation of the SFE extracts of North American ginseng with 15-
31% of methanol in supercritical CO2 as the mobile phase. The effect of temperature and 
pressure on the separation of mixture of ginsenoside standard was tested with the best 
condition being found at T=50°C and P=150 bar. The effect of three types of additives 
including the acidic TFA, basic DIPA, and ionic AA aqueous solution on the separation 
efficiency was examined, with the best selectivity being found in the case of the addition 
of 0.05% v/v TFA in methanol. By adding the additives, the retention time changed with 
the varying amount of additives, indicating the varying solubility of the extract fractions. 
A high-concentration fraction in the SFE extracts of North American ginseng was 
isolated with the SFC system and characterized with NMR,  HPLC-RID, and ESI-MS, 
with its identification being confirmed to be sucrose. 
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Chapter 4  
 
4 Encapsulation of acetyl ginsenoside Rb1 within 
PLGA Microspheres using Microfluidic Technique 
 
Abstract 
Ginsenosides are the active pharmaceutical ingredients (APIs) from ginseng, whose 
herbal extracts have been recognized to have unique pharmaceutical effects. In the 
present study, 6”-O-acetylginsenoside Rb1 (ac-Rb1) isolated from North American 
ginseng, which we have previously shown to have potent immunosuppressive activity, 
was encapsulated within biodegradable poly (DL-lactic-co-glycolic acid) (PLGA) 
microspheres. Both a conventional double emulsion and a microfluidic technique were 
examined for microsphere formation. The ac-Rb1 encapsulation within PLGA 
microspheres was characterized by various physico-chemical techniques including FTIR, 
DSC and XRD. The experimental data showed that the PLGA microspheres produced 
from the microfluidic technique were uniform with tunable mean diameters from 7 to 59 
µm and standard deviations less than 10%. The size was independent of the capillary 
number and could be tuned by altering the continuous and disperse phase flow rate ratios. 
High encapsulation efficiencies were obtained of 75.2%-96.7%. Those obtained from a 
conventional double emulsion method gave sizes in the range of 39 µm to 48 µm and 
standard deviations less than 20%, with lower encapsulation efficiencies of 77.5%-
78.8%. Release profiles of uniform microspheres produced by microfluidics were 
investigated and quantified by UV-Vis spectrophotometry, showing controlled release of 
ac-Rb1 while retaining potency toward immunosuppressive activity using macrophages in 
vitro. This study shows that ac-Rb1 encapsulated PLGA microspheres obtained using the 
microfluidic approach can be utilized for the development of  next-generation biomedical 
agents that are immunosuppressive in drug-release devices. 
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4.1 Introduction 
Of the well known traditional Chinese medicines with biological activity, ginsenosides, 
which are the main active components of plant ginseng, have been widely used as a 
medicinal herbal plant extract [1]. Ginsenosides have been shown to have various 
beneficial health effects including anti-inflammatory, anti-stress and anti-cancer 
properties [2-4]. For instance, ginsenosides Rb1 and Rg1 have been shown as efficient 
neuroprotective agents for spinal cord neurons, while ginsenoside Re did not exhibit such 
activity [5]. We showed that ac-Rb1 ginsenoside (Figure  4.1), which was isolated and 
characterized from North American ginseng, has potent immunosuppressive effects [6] 
and anti-angiogenic effects (Chapter 2). It has also been reported that transformed 
ginsenosides and ginsenoside metabolites show more potency toward cytotoxic activity 
than neutral ginsenosides [7, 8]. However, the oral bioavailability of ginsenosides from 
the gastrointestinal (GI) tract is known to be low, i.e. 5% or less. This is due to 
biotransformation of ginsenosides in the human GI tract by enzymes and intestinal 
bacteria to other ginsenoside-like compounds such as compound K, which is also 
biologically active [9]. Due to the cytotoxicity and poor bioavailability of ginsenosides, 
there is a growing need for more advanced delivery vehicles for ginseng extracts. 
Over the past several years, significant progress has been directed towards developing 
novel delivery systems for bioactive compounds from plant extracts and natural health 
products including nutraceuticals, probiotics, and traditional Chinese medicines [10]. 
Currently, traditional approaches using tablets, capsules, teas, creams, oils, and liquids 
are used for the mixtures of generally low concentrations of biologically active 
compounds. Although some initial work has started investigating various formulations 
for bioactive and plant extracts such as polymeric nanoparticles, nanocapsules, 
liposomes, and microspheres [11-13], very little has been done on investigating 
ginsenosides. Of the microspheres that may be suitable for ginsenosides, PLGA-based 
microspheres are of particular interest due to their long clinical experience, FDA 
compliance, high biocompatibility, appropriate degradation characteristics and 
possibilities for sustained drug delivery. PLGA is one of the most well-known 
biodegradable polymers and delivery carriers for drugs, proteins, peptides and steroids 
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due to its ability to encapsulate a variety of materials [14, 15], although it has not been 
examined with ginsenosides.  
To prepare microspheres, various techniques are possible such as emulsion solvent 
evaporation/extraction methods, phase separation, spray drying and supercritical fluids 
[12, 16]. Conventional microencapsulation methods generate microspheres with broad 
size distributions which influences the kinetics of encapsulant release and limits their 
clinical application [17]. Recently, microfluidic devices have attracted attention due to 
their easy adjustability to create microspheres with controlled morphologies [18]. 
Microfluidic devices utilize low-priced and convenient systems for the control of fluid 
flow [19]. Monodisperse microspheres made from biodegradable polymers have been 
generated by microfluidic devices widely used in drug delivery systems [17]. 
Monodisperse microspheres significantly affect the drug release kinetics, reproducibility, 
and bioavailability of the encapsulant [20]. Several organic (PLA and PLGA) and 
inorganic (chitosan, poly(N-isopropylacrylamide) pNIPAAM, hydrogelator, silk protein, 
pectin, hydrazide and aldehyde-functionalized carbohydrates, dextranhydroxyethyl 
methacrylate (dex-HEMA) and silica) materials have been used for microsphere 
fabrication via microfluidic approach. However, there is no study available regarding 
making monodisperse microspheres containing bioactive plant extract with a microfluidic 
device.  
In this study, we investigate both a microfluidic and a conventional double emulsion 
technique for ac-Rb1 loaded PLGA microspheres. Their encapsulation, release and 
bioactivity are measured. 
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Figure  4.1. a) Acetyl ginsenoside Rb1 (ac-Rb1) structure, b) PLGA structure. 
 
4.2 Materials and Methods 
4.2.1 Materials 
6”-O-acetylginsenoside Rb1 (ac-Rb1) was isolated and fractionated from North American 
ginseng root as previously described [6]. Poly (DL-lactide-co-glycolide) (PLGA) (75:25, 
MW 66-107 kDa), poly (vinyl alcohol) (PVA) (87-89% hydrolyzed, MW 13-23 kDa), 0.1 
mol/L phosphate buffered solution (PBS, pH 7.4), dichloromethane (DCM) of HPLC 
grade (>99.9%), methanol and ethanol were purchased from Sigma-Aldrich, Canada and 
used as received. Poly(dimethylsiloxane) (PDMS; Sylgard 184) was obtained from Dow 
Corning (Midland, USA) used for preparation of microfluidic microchip. Purified water 
was produced from a Milli-Q water purification system (18.2 MΩ·cm 
resistivity, Barnstead EasyPureII, Thermo Scientific, USA). RAW 264.7 (ATCC TIB 67) 
murine macrophage cell lines were provided by Dr. Jeff Dixon (Department of 
Physiology and Pharmacology, Western University, Canada). BD OptEIA ELISA kits 
tumour necrosis factor-α were provided by BD Biosciences (Bedford, MA, USA). LPS 
(Lipopolysaccharides) from Escherichia coli (0111:B4) purity>99%, Dexamethasone 
purity>98% and Griess reagent were purchased from Sigma-Aldrich (USA). Cell culture 
medium and reagents were purchased from Gibco laboratories (USA). 
a) b) 
103 
 
4.2.2 Preparation of ac-Rb1 loaded PLGA microsphere 
A microfluidic method was used to prepare the ac-Rb1 encapsulated PLGA microspheres. 
The schematic of the microfluidic apparatus is shown in Figure  4.2. A microfluidic chip 
with channel dimensions of 100 µm in height and 200 µm in width was fabricated by soft 
lithography techniques [21] in collaboration with Dr. Jun Yang, Mechanical and Material 
Engineering Department, Western University, Canada. The microfluidic chips were 
molded by a mixture of PDMS elastomer base/curing agent in 10:1 ratio from SU-8 mold 
and bonded to a flat PDMS substrate under plasma treatment for 35 s in a PX-250 plasma 
chamber (March Instruments, Concord, MA) and then immediately placed in contact to 
bond the surfaces irreversibly. The devices were then bonded using a homemade UV-
ozone generator. We dissolved 10 mg of ac-Rb1 in 5 mL of solution (methanol: de-
ionized water (2:3 v/v)) and 100 mg of PLGA was dissolved in 10 mL of DCM. The ac-
Rb1 solution was emulsified in PLGA organic solution (oil-phase) to form the disperse 
phase. The micro channels were first filled with a continuous phase of 2% PVA aqueous 
solution before introducing the organic (disperse) phase [17, 19]. Digitally controlled 
syringe pumps (KD scientific pump, Inc. Legato 2200, 1100) delivered liquid phase into 
the microfluidic device at constant flow rates using Teflon tubing (1.6 mm OD, 0.6 mm 
ID). The flow rate of the continuous phase was in the range between 0.05-0.2 mL/min 
while that of disperse phase was kept at a constant value of 0.01 mL/min as summarized 
in Table  5.1. At the end of the device outlet, the Teflon tubing was submerged into a 10-
mL beaker containing 1% of PVA aqueous solution at 40°C to collect the droplets. Next, 
the solvent was removed from the droplets by evaporation. The formed microspheres 
were then centrifuged at 4500 rpm for 5 min followed by washing with de-ionized water 
three times to remove excess PVA and freeze-drying then stored at −20°C.  
 
104 
 
 
Figure  4.2. Schematic drawing of microfluidic system: (1) dispersed phase inlet (Acetyl 
ginsenoside Rb1 solution dissolved in PLGA in DCM solution), (2) continuous phase 
inlet (2% PVA aqueous solution), (3) outlet. 
As a comparison to the microfluidic technique, the widely applied water-in-oil-in-water 
(w/o/w) double emulsion method [22] was utilized for the formation of ac-Rb1-loaded 
PLGA microspheres (Figure  4.3). Briefly, 10 mg of ac-Rb1 was dissolved in 5 mL of 
solution (methanol: de-ionized water (2:3 v/v)) and 100 mg of PLGA was dissolved in 10 
mL of DCM. The ac-Rb1 solution was emulsified in the PLGA solution using a magnetic 
stirring bar at three different speeds of 800, 1000 and 1200 rpm summarized in Table  4.1. 
The entire mixture (w/o) was added to a 2% of PVA aqueous solution and emulsified 
again to generate the double emulsion (w/o/w), which was subsequently poured into 40 
mL of de-ionized water and stirred at 400 rpm for 3 hr. After removing DMC by 
evaporation, the formed microspheres were centrifuged at 4500 rpm for 5 min, followed 
by washing with de-ionized water three times to remove PVA and freeze-drying to 
remove water. The ac-Rb1 loaded PLGA microspheres were stored at −20°C.  
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Figure  4.3. Schematic of the double emulsion method. 
4.2.3 Determination of ac-Rb1 content in the PLGA microspheres 
The ac-Rb1 concentration encapsulated inside the PLGA microspheres was measured 
using a UV spectrophotometer (Shimadzu UV-Vis 3600) in triplicate at 203 nm. First, a 
standard calibration curve of ac-Rb1 was established using the UV spectrophotometer by 
measuring the absorbance as a function of concentration. To measure the ac-Rb1 content 
after PLGA encapsulation,
  
5 mg of ac-Rb1-loaded microspheres were dissolved in 1 mL 
of DCM, which was subsequently evaporated with the residue then dissolved in 1 mL of 
methanol.  The ac-Rb1 content was analyzed by the UV spectrometer based on the 
calibration curve established from ac-Rb1 standard solution mixtures. The ac-Rb1 
encapsulation efficiency (EE%) was calculated via the following equation  
100(TL%)  LoadinglTheoretica
(DL%)  LoadingDrug%EE ×= ,                         (4.1) 
where 
100
esmicrospher  PLGAofweight 
erspectromet by UV measured  PLGAin Rb1-ac ofweight %)(DL  LoadingDrug ×= ,     (4.2a)
100
  PLGAofweight  Rb1-ac ofweight 
system  toadded Rb1-ac ofweight %)(TL  LoadinglTheoretica ×
+
= .     (4.2b) 
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4.2.4 Ac-Rb1 delivery carriers characterization 
The surface morphology of the PLGA microspheres systems was measured using a 
scanning electron microscope (Hitachi S-4500). Samples were sputtered with gold 
coating, and placed on a copper stub. Also, an Axioimager Z1 motorized upright 
fluorescence microscope was used to acquire images of the polydisperse and 
monodisperse PLGA microspheres. Melting points were measured by a DSC Q200 (TA 
Instrument, New Castle, Delaware, USA). The scanning rate was 10 oC/min, with a 
scanning temperature range of 25–250 oC. XRD data were obtained for ac-Rb1, placebo 
microspheres, and ac-Rb1-loaded microspheres to evaluate the crystallinity after 
encapsulation (Inel CPS Powder Diffractometer). Scanning was done up to a 2Θ angle of 
43o using a powder diffractometer instrument which was equipped with a Cu-X-ray 
radiation Tube, an Inel XRG3000 generator and an Inel CPS 120 detector. ATR-FTIR 
(Nicolet 6700, Thermo Scientific) was used to investigate the cross-linked core-shell 
composites in the range of 500-4000 cm−1. 
4.2.5 Kinetic release studies of ac-Rb1 
The ac-Rb1 concentration encapsulated within the PLGA microspheres was measured 
using a UV spectrophotometer (Shimadzu UV-Vis 3600) in triplicate at 203 nm as 
described in section 4.2.3. For the release studies, 5 mg of ac-Rb1-loaded PLGA 
microspheres were suspended in 10 mL PBS (pH=7.4) at 37°C with shaking at 50-100 
rpm. At predetermined time intervals, the solution was centrifuged at 2000 rpm for 5 min, 
with 2 mL of supernatant then collected and replaced with 2 mL of fresh PBS. The ac-
Rb1 content in the supernatant was determined at a wavelength of 203 nm using a UV 
spectrophotometer (Shimadzu UV-Vis 3600). All experiments for each time interval were 
repeated in triplicate. The cumulative release of ac-Rb1 profiles were acquired with the 
volume loss correction.  
4.2.6 Bioactivity of released ac-Rb1 
The mouse macrophage cell line RAW 264.7 was cultured in Dulbeccos Modified Eagle's 
Medium supplemented with 10% FBS, 25 mM HEPES, 2 mM Glutamine, 100 IU 
penicillin/ml, and streptomycin 100 µg/mL. The pH of the medium was around 7.4. The 
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cells were kept at 37°C in a humidified incubator with 5% CO2, and seeded in 96-well 
tissue culture plates at a density of 1.5×105 cells per well. Our previous study showed that 
ac-Rb1 has potency toward immunosuppressive activity on murine macrophages [6]. In 
this study, the inhibitory effect of released ac-Rb1 from the microspheres in vitro was 
evaluated. To examine the inhibitory effect of ac-Rb1 released from PLGA microspheres 
after 400 h, 5-150 µg/mL of ac-Rb1 before encapsulation and after being released from 
PLGA microspheres were added to the macrophages 2h prior to the addition of  LPS. In 
this study, dexamethasone (DEX) was used as a positive control for the suppression of 
LPS-induced stimulation of macrophages. So, cultured macrophages were incubated with 
DEX (5 µM) for 2 hr prior to the addition of LPS. The 24-hour cytokine production 
induced by LPS was determined by measuring NO and TNF-α levels in the culture 
medium. TNF-α concentrations in supernatants from cultured cells were analyzed with 
ELISA. Samples were assessed with mouse cytokine-specific BD OptEIA ELISA kits 
(BD Biosciences, USA) according to the manufacturer's protocol. Sample nitrite 
concentrations in culture medium were determined by means of Griess reagent (0.5% 
sulfanilic acid, 0.002% N-1-naphtyl-ethylenediamine dihydrochloride, 14% glacial acetic 
acid). Culture supernatant of each sample and the Griess reagent (50 µL each) were 
added to a 96-well plate. The measurements of absorbance were conducted at a 
wavelength of 550 nm using a Multiskan Spectrum microplate reader (Thermo Fisher 
Scientific, Finland) with SkanIt software (version 2.4.2, Thermo Fisher Scientific, 
Finland). Nitrite concentrations were calculated from a sodium nitrite standards 
calibration curve. 
4.2.7 Statistics 
All experiments were performed at least three times with statistical analysis 
accomplished using GraphPad prism 4.0a Software (GraphPad Software Inc., USA). Data 
were reported  based on mean ± standard deviation (SD) of three sets of experiments. 
Data sets with multiple comparisons were evaluated by one-way analysis of variance 
(ANOVA) with Tukey’s and Dunnett’s post-hoc test. p < 0.05 was considered to be 
statistically significant. 
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4.3 Results and Discussion 
4.3.1 Characterization of the microspheres  
Ac-Rb1-loaded PLGA microspheres were prepared comparing both a conventional 
double emulsion method and by microfluidics. The experimental parameters and 
characteristics of the examined formulations of microspheres are listed in Table  4.1.  
Table  4.1. Formulation parameters and characteristics of ac-Rb1-loaded PLGA 
microspheres with microfluidic and conventional double emulsion methods. 
*under this experimental condition, no microsphere was formed. 
Formulation disperse phase 
flow (mL/min) 
continuous phase 
flow (mL/min) 
average 
size  
(µm) 
Std. Dev. 
(µm) 
EE 
(%) 
MF-1 0.01 0.05 *n.a *n.a *n.a 
MF-2 0.01 0.08 59 6 96.7 
MF-3 0.01 0.1 57 5 96.5 
MF-4 0.01 0.15 40 9 93.3 
MF-5 0.01 0.2 7 2 75.2 
 First emulsion  
Stirrer speed 
(rpm) 
Second emulsion 
Stirrer speed 
(rpm) 
average 
size  
(µm) 
Std. Dev. 
(µm) 
EE 
(%) 
DE-6 800 400 48 19 77.5 
DE-7 1000 400 41 24 78.5 
DE-8 1200 400 39 15 78.8 
  
Figure  4.4a-c shows the size and morphology of 
double emulsion method
spherical morphology with a broad size
the microspheres was analyzed 
 4.5, revealing an average size of 
size of the microspheres decreased with increasing stirring speed, agreeing well with the 
results reported in the literature
 
Figure  4.4. PLGA microspheres from double emulsion method
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Figure  4.5. Image J number of size distribution for ac-Rb1-loaded PLGA microsphere: a) 
DE-6, b) DE-7 and c) DE-8. 
Figure  4.6a-c shows the size and morphology of microspheres produced from the 
microfluidic method by SEM and ZIESS light microscopy. The samples have a similar 
spherical morphology to the microspheres prepared using the double emulsion method, 
however the microfluidic approach gave much more uniform microspheres (50-65 µm) 
compared to the double emulsion method (10-70 µm). Also, Figure  4.7 shows the size 
distributions of the microspheres which were obtained using Image J software, showing a 
uniform distribution with standard deviations between 2 µm and 9 µm. 
 
  
 
Figure  4.6. PLGA microspheres from microfluidic method where the disperse phase flow 
included ac-Rb1 solution emulsified in PLGA organic solvent solution, and continuous 
phase flow contained 2% PVA aqueous solution. The continuous phase flow rate was 0.1 
mL/min while the disperse phase flow rate was 0.01 mL/min. a, b) Scanning Electron 
Microscopy results and c) Zeiss Light Microscopy results.  
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Figure  4.7. Image J number of size distribution for ac-Rb1-loaded PLGA microsphere: a) 
MF-2, b) MF-3, c) MF-4, d) MF-5. 
In the microfluidic approach, the flow rate ratio of the continuous phase to the disperse 
phase had a significant effect on the formation of microspheres. It should be pointed out 
that increasing the disperse phase flow rate from 0.001 mL/min to 0.01 mL/min led to 
blocking of the inlet microchannel, preventing the formation of microspheres. Also, when 
the disperse phase flow rate was higher than 0.01 mL/min and higher than the continuous 
phase flow rate, microsphere particles were not formed. The relationship between the 
average microsphere size and the continuous phase flow rate is given in Figure  4.8. As 
the flow rate of the continuous phase increased from 0.08 mL/min to 0.20 mL/min, while 
that of the disperse phase was kept at 0.01 mL/min, the average size of the formed 
microspheres decreased from 59 µm to 7 µm. However, by lowering the flow rate of the 
continuous phase to 0.05 mL/min, no microspheres were formed. Our experimental 
results show that the microsphere size obtained with the microfluidic method are tunable 
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by changing the flow rate, although only a narrow experimental window enabled 
microsphere formation. 
 
Figure  4.8. Effect of continuous phase flow rate on the microsphere size at the disperse 
phase flow rate of 0.01 mL/min. 
In order to provide a better understanding of these results, the Reynolds number (Re) and 
the capillary number (Ca) need to be considered. Flow in microfluidic systems usually 
have a low value of Reynolds number which indicates that the flow is laminar. The 
Reynolds number defined as: Re = ρud/µ  where ρ is the density of the continuous phase, 
u is the velocity of the continuous phase, d is the characteristic length scale (e.g. the 
hydraulic diameter of the channel cross-section), and µ  is the viscosity of the continuous 
phase. The dimensionless capillary number has a significant role in determining the 
droplet break off. The capillary number is defined as: Ca = µu/γ  where µ  is the viscosity 
of the continuous phase, u is the velocity of the continuous phase, and γ is the interfacial 
tension between the oil and water phases. In the microfluidic system, the formation of 
microspheres is governed by the competition between the viscous forces and the 
interfacial forces. At high values of Ca (greater than 0.01), the viscous forces play a 
significant role in the process of the microsphere break-up in the junction. As the droplet 
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enters the main channel, it is exposed to a viscous force from the continuous phase to the 
point that it breaks off near the junction without blocking the entire cross-section, which 
is called the shearing regime [24]. At low values of Ca (typically less than 0.01), 
interfacial forces dominate over viscous forces. As a result, the viscous force on the 
interface of the droplet which enters the main channel are not adequate to deform it. 
Consequently, the droplet blocks almost the whole cross-section of the main channel. If 
the flow rate of the disperse phase is higher than the flow rate of the continuous phase, 
the droplet is elongated and the thin film was created from the extending neck. 
Ultimately, break-up occurs after the disconnection of the dispersed phase from the 
junction due to the pressure drop across the droplet. However, when the disperse phase 
flow rate is lower than the continuous phase flow rate, the droplet does not find enough 
time to elongate and break-up happens directly after the droplet blocks the entire cross-
section of the main channel. In this study, we chose the disperse flow rate lower than the 
continuous phase flow rate so the disconnection occurs at the junction which is believed 
to be a more stable process in the droplet formation [25]. Table  4.2 shows the values for 
Ca and Re numbers used in this work which were calculated based on the utilized 
microfluidic device geometry and the continuous phase properties. The low values of 
Reynolds number confirm that the flow is laminar. The results show that Ca is lower than 
0.01 which according to the literature [24] implies that the size of microspheres is 
independent of Ca and mainly determined by the ratios of the disperse and the continuous 
phases flow rates. 
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Table  4.2. Values of Capillary (Ca) and Reynolds (Re) at different continous phase flow 
rate (Qc). 
Qd (mL/min) Qc (mL/min) Ca Re 
0.01 0.05 1.7×10−3 6.18 
0.01 0.08 2.7×10−3 9.89 
0.01 0.1 3.4×10−3 12.37 
0.01 0.15 5.1×10−3 18.55 
0.01 0.2 6.8×10−3 24.74 
 
There are several numerical methods using computational fluid dynamics (CFD) that 
have been developed to model microsphere formation and the mechanism of droplet 
formation [24, 26, 27]. Accurate simulation however remains challenging as it deals with 
microsphere formation of a disperse phase within a continuous phase which is an 
unsteady process of moving fluid-fluid interfaces and is therefore a complex flow 
problem [25]. Figure  4.9 represents the preliminary results showing the above explained 
phenomena in this studied condition when the disperse flow rate is lower than the 
continuous phase flow rate. For this case, the droplet does not have time to elongate and 
therefore break-up happens immediately after the droplet blocks the entire cross-section 
of the main channel as is shown in Figure  4.9. However, future investigation is needed to 
simulate the process and mechanism of microsphere formation which is a complex 
phenomenon. 
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Figure  4.9. Schematic of T-junction microchannel. Where the disperse phase flow 
included ac-Rb1 solution emulsified in PLGA organic solvent solution (red) and 
continuous phase flow contained 2% PVA aqueous solution (blue). The continuous phase 
flow rate was 0.1 mL/min while the disperse phase flow rate was 0.01 mL/min. The 
droplet does not have time to elongate and break-up happens immediately after the 
droplet blocks the entire cross-section of the main channel. 
4.3.2 Encapsulation of ac-Rb1 within PLGA microspheres 
In order to measure the ac-Rb1 concentration encapsulated within the PLGA microspheres 
required to determine encapsulation efficiency and subsequent drug release, UV 
spectrometry was utilized as shown in Figure  4.10. A standard calibration curve of ac-
Rb1 in the range of 100 µg/mL to 300 µg/mL was plotted by measuring the absorbance as 
a function of concentration. The ac-Rb1 has a maximum absorbance at 203 nm. The 
relation between the concentration and the intensity of absorbance can be described as 
shown in Figure  4.10. 
.  
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Figure  4.10. UV-Vis absorption spectra and the calibration curve of standard ac-Rb1. 
Figure  4.11 shows the encapsulation efficiency calculated for microspheres obtained 
from both the double emulsion and microfluidic methods. According to Equation (4.1) 
and Figure  4.11, the ac-Rb1 encapsulation efficiency of 96.7%, 96.5%, 93.3% and 75.2% 
was obtained using four formulations of MF-2, MF-3, MF-4 and MF-5, respectively. For 
the microfluidic method, the ac-Rb1 encapsulation efficiency increased with increasing 
average size of the microspheres. However, microspheres obtained from the conventional 
double emulsion method gave a lower encapsulation efficiency of 77.5% - 78.8% with 
the narrowest size distribution obtained using DE-8 at 10 - 70 µm.  
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Figure  4.11.  Encapsulation efficiency of the microspheres obtained from a) double 
emulsion method and b) microfluidic method. 
These results (Table  4.1 and Figure  4.7) reveal that compared to the double emulsion 
method, more uniform microspheres with higher encapsulation efficiency were obtained 
using the microfluidic method. These results are in agreement with those reported in the 
literature where the poly(L-lactic acid) polymeric microspheres obtained from 
microfluidics were significantly better in terms of encapsulation efficiency than the 
microspheres fabricated by other methods such as conventional double emulsion method, 
spray drying and supercritical anti-solvent methods [17]. Encapsulation efficiency is an 
important factor in drug delivery, especially for valuable and expensive bioactive 
compounds. Formulation MF-3 generated the most uniform microspheres with the 
narrowest size distribution (Figure  4.7b) with an average size of 57 µm and EE% of 96.5. 
It was selected for further development of the drug delivery systems as examined in more 
detail below. 
To confirm the presence of ac-Rb1 in the PLGA microspheres, the FTIR spectra of ac-
Rb1, pure PLGA, and ac-Rb1 loaded microspheres are compared in Figure  4.12. In the 
FTIR spectrum of the ac-Rb1 (Figure  4.12a), the peaks at 1726 and 1021 cm-1 are 
attributed to the C=O and C-O stretching vibrations of an acetic ester group, respectively. 
Also, the peaks at 3304 and 1643 cm-1 are assigned to the OH of the sugar moieties in the 
ac-Rb1 [6].  In the FTIR spectrum of pure PLGA (Figure  4.12b), the peak at 1740 cm-1 is 
assigned to the absorbance of C=O in PLGA [28-30]. The spectrum of ac-Rb1 loaded 
PLGA microspheres (Figure  4.12c) showed all the peaks appearing in the spectrum of 
A) B) 
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pure PLGA and additional hydroxyl peaks from ac-Rb1 at 3303 and 1643 cm-1, indicating 
successful encapsulation of ac-Rb1 in the PLGA matrix. It should be noted that in the 
encapsulation process of ac-Rb1 in PLGA microsphere, the products were freeze-dried at 
the end to eliminate any residual water which may have similar peaks in the region of 
3304 and 1643 cm-1. 
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Figure  4.12. FTIR results for a) ac-Rb1; b) pure PLGA; c) ac-Rb1 encapsulated in PLGA 
microsphere obtained from microfluidic method. 
In order to investigate the physical state of the encapsulated ac-Rb1 in the microspheres, 
DSC and XRD were employed [31]. DSC thermograms of ac-Rb1, ac-Rb1-loaded PLGA 
micropheres, and placebo PLGA microspheres are shown in Figure  4.13A. Ac-Rb1 shows 
a sharp endothermic peak (Figure  4.13A-a) at 54 °C attributed to the melting point of ac-
Rb1. A small peak at 99°C is due to the loss of moisture. In Figure  4.13A-c, the placebo 
microspheres show two endothermic peaks at 51°C and 100°C which are due to the 
PLGA glass transition temperature (Tg) [32, 33] and the loss of moisture, respectively. In 
Figure  4.13A-b, the ac-Rb1-loaded microspheres demonstrate all the endothermic peaks 
available in the thermograms of placebo microspheres, however there is no peak 
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corresponding to ac-Rb1, which is consistent with molecular-level dispersion of ac-Rb1 in 
the polymer microspheres. The amorphous state of ac-Rb1 in the microspheres was also 
confirmed by XRD (Figure  4.13B), as the crystalline peak at 2θ=4o, which shows the 
semi-crystalline nature of ac-Rb1, disappeared after being encapsulated within the 
microspheres. 
 
 
 
Figure  4.13. A) DSC thermograms of a) ac-Rb1, b) ac-Rb1-loaded PLGA microspheres 
obtained from microfluidic method, and c) placebo PLGA microspheres obtained from 
microfluidic method; B) XRD patterns of: a) ac-Rb1-loaded PLGA microspheres obtained 
from microfluidic method, b) placebo PLGA microspheres obtained from microfluidic 
method, and c) ac- Rb1. 
4.3.3 In Vitro ac-Rb1 release and release kinetics  
Release kinetics of the ac-Rb1 from both the monodisperse and polydisperse 
microspheres are compared in Figure  4.14. Each point on this figure represents the 
average of three experimental data points. The ac-Rb1 release profile shows faster release 
kinetics in the first 100 h followed by a slow steady release from 100 h to 400 h. The 
observed burst effect may be due to ac-Rb1 molecules that are at or near the PLGA 
microsphere surface. Our FTIR results showed that ac-Rb1 was observable, which would 
indicate some surface enrichment, although the XRD indicated molecular integration, 
thus either complete micromixing or some surface dispersion cannot be ruled out. As can 
be seen in Figure  4.14B, the initial burst release of ac-Rb1 from the monodisperse 
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microspheres in the first 100 h is considerably smaller than that from the polydisperse 
microspheres [19]. From Figure  4.14A, the total cumulative ac-Rb1 release is 46% from 
the monodisperse microspheres and 81% from the polydisperse microspheres. The 
release profile of ac-Rb1 from the monodisperse microspheres prepared by the 
microfluidic method is slower than that from the polydisperse samples. Although the 
large burst effect can release a therapeutic agent ac-Rb1 relatively fast, it might also 
damage tissues around the treatment site [22]. Therefore the smaller burst effect may be 
advantageous.  
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Figure  4.14. A) Release profiles of ac-Rb1 from  PLGA microspheres produced by 
double emulsion method (DE-8);  PLGA microspheres produced by microfluidic 
method (MF-3); B) enlargement of release profile to magnify the burst effect. Releasing 
medium was PBS (pH=7.4) at 37°C with shaking at 50-100 rpm. 
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4.3.4 Bioactivity of released ac-Rb1 
Our results previously showed that ac-Rb1 ginsenoside has potent immunosuppressive 
effects [6]. For the current study, the immunosuppressive activity of released ac-Rb1 from 
both types of microspheres obtained via the microfluidic method and the double emulsion 
method was examined by bioassay analysis using macrophages in vitro. The effect of ac-
Rb1 treatment on LPS-stimulated NO and TNF-α production in macrophages can be seen 
in Figure  4.15. This figure shows that ac-Rb1 released from the PLGA microspheres from 
both the microfluidic and double emulsion methods significantly inhibits the production 
of NO and TNF-α, in LPS-induced RAW 264.7 macrophages. This inhibition occurs in a 
dose-dependent manner within the dose range of 5-150 µg/mL released ac-Rb1 extract. 
The immunosuppressive activity of ac-Rb1 did not change significantly before 
encapsulation within the carrier and after release from the delivery carrier.  Also, the 
microsphere preparation method does not have significant effect on the 
immunosuppressive activity of ac-Rb1. Figure  4.15 also shows that the influence of ac-
Rb1 is inflammatory mediator-specific i.e. the magnitude of inhibition by ac-Rb1 before 
encapsulation and after release from the delivery carriers was much greater with respect 
to NO production. The released ac-Rb1 inhibited the LPS-induced NO production more 
significantly with the lowest level of NO production around 5 µM and 7 µM  in presence 
of 150 µg/mL released ac-Rb1 from PLGA microspheres produced by microfluidic 
method and double emulsion method, respectively. 
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Figure  4.15. Inhibitory effect of ac-Rb1 released from microspheres obtained via (first 
row) microfluidic method and (second row) double emulsion method. Inhibitory effect of 
ac-Rb1 on LPS-stimulated 24 hr macrophage production of  a, c) NO and b, d) TNF-α. 
Murine macrophages (RAW 264.7 cells) were pre-treated with the ac-Rb1 ginsenoside 
and dexamethasone (DEX) for two hours after which LPS (1 µg/mL) was added, and the 
culture supernatants were analyzed for NO and TNF-α by Griess reaction assay and 
ELISA, respectively. Dexamethasone (DEX) at 5 µM was used as a positive control. 
Three independent experiments were performed and the data were shown as mean ± SD. 
Datasets were evaluated by ANOVA. #Values p<0.05 Significantly different from LPS-
induced group. 
 
4.4 Conclusions 
Ac-Rb1 was encapsulated in PLGA microspheres using different variations of the 
microfluidic method and conventional double emulsion method, with the first method 
generating microspheres of more uniform size. The microspheres were characterized by 
SEM, FTIR, DSC, and XRD to examine the morphology and the physical state of ac-Rb1 
in the microspheres. The monodisperse microspheres produced by a microfluidic method 
(50-65 µm) were found to exhibit a slower release rate and a smaller burst effect than the 
polydisperse microspheres prepared using a double emulsion method (10-70 µm). 
Moreover, the released ac-Rb1 from delivery systems showed immunosuppressive effect 
on LPS-induced macrophages, revealing that the microsphere preparation method does 
not change the bioactivity of ac-Rb1 in vitro. The bioactive plant extract ac-Rb1 
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encapsulated within PLGA microsphere could provide many potential applications in 
pharmaceutical industries . 
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Chapter 5  
 
5 PLGA Microsphere/Gelatin Hydrogel Combination 
Systems for the Delivery of acetyl ginsenoside Rb1  
 
Abstract 
Recently we showed that 6”-O-acetylginsenoside Rb1 (ac-Rb1) could be isolated from 
North American ginseng, and that is showed potent immunosuppressive activity using in 
vitro studies (Chapter 2). However, application of ginsensosides using conventional 
herbal release strategies has been limited due to their low oral bioavailability and 
cytotoxicity.  In the present study, a drug delivery system for release of ac-Rb1 was 
developed and investigated for the first time by forming core-shell structures of  
biodegradable poly (DL-lactic-co-glycolic acid) (PLGA) microspheres as the core with a 
gelatin hydrogel shell. The core-shell systems were characterized by various physico-
chemical testing (SEM, FTIR, DSC, TGA). Release profiles were studied and quantified 
by UV-Vis spectrophotometry showing that the release of ac-Rb1 from the gelatin shell 
slowed any burst effect and allowed tuning of the release profile by controlling the cross-
linking density. The core-shell structures releasing ac-Rb1 showed potency toward 
immunosuppressive activity using macrophages in vitro. The  release data results were 
further analyzed using empirical equations which followed a Fickian diffusion release 
mechanism that could be controlled by tuning these hybrid structures. This approach 
shows utility for the development of  next-generation drug-release devices using 
ginsenosides. 
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5.1 Introduction 
Recent interest has turned to plants as a source of either new drugs or of compounds from 
which more efficacious or less toxic pharmaceutics can be developed based on their long-
standing use in traditional medicine [1]. These compounds are believed to work more 
slowly and gently than pharmacologic drugs, and are less likely to cause serious side 
effects and toxicity [2-4]. Of the well known traditional Chinese medicines with 
biological activity, ginseng has been widely used as a medicinal herbal plant [5]. Similar 
to Asian ginseng, North American ginseng is also bioactive in which the main active 
components are ginsenosides, which have been shown to have various beneficial health 
effects including anti-inflammatory, anti-stress, and anti-cancer properties [6-8].  
Recently, interest has shifted to study the effects of individual ginsenosides [6, 9-11] due 
to their unique therapeutic properties which may play a role in next-generation 
pharmaceutics [12, 13]. For instance, ginsenoside Rb1 which is the major ginsenoside in 
North American ginseng, has exhibited inhibition of proinflammatory cytokine responses 
for both lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor 
(TNF)-α production in mice [14, 15]. This ginsenoside has also shown anti-angiogenic 
activity in-vivo, inhibiting the growth of new blood vessels and thus is being used to treat 
cancer [10]. Moreover, ginsenosides Rb1 and Rg1 have been examined as efficient 
neuroprotective agents for spinal cord neurons, while ginsenoside Re did not exhibit such 
activity [11]. We have been investigating 6”-O-acetylginsenoside Rb1 (ac-Rb1), which 
was isolated from North American ginseng root, giving potent immunosuppressive 
properties [16]. It has also been reported that transformed ginsenosides and ginsenoside 
metabolites have shown more potency toward cytotoxic activity than neutral ginsenosides 
[17, 18]. However, the oral bioavailability of ginsenosides from the gastrointestinal (GI) 
tract is known to be low, i.e. 5% or less. This is because the ginsenosides are extensively 
biotransformed in the human GI tract by enzymes and intestinal bacteria to other 
ginsenoside-like compounds such as compound K, which is also biologically active [13]. 
To date, no work has been done in the delivery of individual ginsenosides with different 
biological activities. 
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Different formulations such as polymeric nanoparticles, nanocapsules, liposomes, and 
microspheres have been investigated for bioactive and plant extract delivery [19-21]. For 
ginseng extracts, tablets and capsules are available on the market [22]. Recently Xiao et 
al. [23] developed an injectable biocompatible hydrogel system that can release 
dexamethasone which has similar immunosuppressive activity as ginsenoside ac-Rb1  
(which in Chapter 2 is used as a control for studying the inhibitory effect of ac-Rb1). This 
hydrogel injected into joint tissue could release drug in response to mechanical forces. 
Non-oral delivery systems are of interest for ginsenosides to be delivered via other 
administration routes such as intranasal, injection or transdermal patches to take 
advantage of these immunosupressive and anti-angionenic properties [12, 24-26]. In 
designing these new delivery systems for ginsenosides, similar to conventional drug 
delivery systems, a high encapsulation efficiency, controlled release behavior, superior 
bioavailability, low toxicity, and low side effects are required [19, 20, 27]. Potential 
delivery carriers for bioactive compounds of plant extracts are polymer microspheres 
such as poly-α-cyanoacrylate alkyl esters, polyvinyl alcohol, natural polymers (albumin, 
gelatin and vegetable protein) or polysaccharides (cellulose, starch and its derivatives, 
alginate, chitin and chitosan) [20]. PLGA-based microspheres are of particular interest 
due to PLGA's excellent biocompatibility, complete biodegradability, FDA compliance, 
and easy administration [28]. However, the effectiveness of PLGA microspheres may be 
limited by continued removal by macrophages [29, 30]. Gelatin, a natural polymer 
derived from collagen with a variety of pharmaceutical and medical applications, has 
been extensively used as a hydrogel carrier for site-specific drug delivery via different 
administration routes such as intranasal, injection or transdermal [31]. However, release 
from gelatin hydrogels can have high initial burst rates at the beginning before slowing to 
a low, constant level. While the burst effect can provide a therapeutic function in the 
treatment of acute disease, it can also lead to tissue damage around the injection or 
dermal site. Therefore, a microsphere/hydrogel combination system could be a better 
choice to achieve localized delivery which would take advantage of both individual 
carriers, providing a tunable delivery approach, as previously shown by Liu et al. [28].  
Previously in Chapter 4 [32], we examined the encapsulation of ac-Rb1 within PLGA 
microspheres prepared by both a microfluidic and a double emulsion method. In this 
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study, the microspheres containing ac-Rb1 were embedded within a gelatin hydrogel to 
form core-shell structures with tunable shells. The release behavior of ac-Rb1 from the 
gelatin encapsulated hybrids was investigated in simulated body fluid at 37°C by UV-Vis 
spectrometry. Their immunosuppresive activity using macrophages in vitro was also 
confirmed. The kinetics of ac-Rb1 release from these systems was compared using 
empirical equations (Hixon-Crowell, Korsmeyer-Peppas, Weibull, and first-order 
models) to determine the best mechanism of experimentally obtained in vitro release 
data. 
 
5.2 Materials and methods 
5.2.1 Materials 
6”-O-acetylginsenoside Rb1 (ac-Rb1) was isolated and fractionated from North American 
ginseng root as previously described [16]. Gelatin from porcine skin, glutaraldehyde 25% 
in H2O, 0.1 mol/L phosphate buffered solution (PBS, pH 7.4), dichloromethane (DCM) 
of HPLC grade (>99.9%), methanol, ethanol, acetic acid, and ammonium hydroxide were 
purchased from Sigma-Aldrich, Canada and used as received. Purified water was 
produced from a Milli-Q water purification system (18.2 MΩ·cm resistivity, Barnstead 
EasyPureII, Thermo Scientific, USA). RAW 264.7 (ATCC TIB 67) murine macrophage 
cell lines were provided by Dr. Jeff Dixon (Department of Physiology and Pharmacology, 
Western University, Canada). BD OptEIA ELISA kits tumour necrosis factor-α were 
provided by BD Biosciences (Bedford, MA, USA). LPS (Lipopolysaccharides) from 
Escherichia coli (0111:B4) purity>99%, Dexamethasone purity>98% and Griess reagent 
were purchased from Sigma-Aldrich (USA). Cell culture medium and reagents were 
purchased from Gibco laboratories (USA). 
5.2.2 Preparation of gelatin hydrogel shell 
PLGA microsphere cores containing ac-Rb1 were prepared as previously described [32]. 
The monodisperse microspheres prepared from the microfluidic approach were used for 
further delivery and release studies due to their narrow size distribution and more 
131 
 
uniform morphology. The schematic illustration of the process for preparing ac-Rb1 
loaded PLGA microsphere encapsulated into gelatin hydrogel is shown in Figure  5.1. For 
core encapsulation, 5% (w/w) of gelatin aqueous solution was prepared by dissolving 
gelatin powder in distilled water at 55-60 ºC for 2 hr. Then 10 mg of ac-Rb1-loaded 
PLGA microspheres were dispersed in 500 µL of distilled water, and added to 4 mL of 
the above gelatin solution with stirring. Glutaraldehyde 25%, was examined as a 
crosslinking agent at various concentrations: 0, 10, 50, and 100 µL by adding dropwise 
under stirring at room temperature to form stable gels. The product was washed with 
double distilled water and then centrifuged at 4500 rpm for 10 min followed by washing 
with de-ionized water 3X to separate the solid gels, which were subsequently  poured into 
Petri dishes, freeze-dried,  then stored in a desiccator.  
 
 
 
Figure  5.1. Schematic illustration of the process for preparing ac-Rb1 loaded PLGA 
microsphere encapsulated into gelatin hydrogel. 
5.2.3 Characterization of core-shell structures 
The surface morphology of the gelatin coated core-shell systems were determined using 
scanning electron microscope (Hitachi S-4500). Samples were sputtered with gold 
coating, then placed on a copper stub. Melting points were measured by a DSC Q200 
(TA Instrument, New Castle, Delaware, USA). The scanning rate was 10 oC/min, with a 
scanning temperature range of 25–250 oC. Thermal degradation measurements were 
carried out using a TGA (TA Instrument, New Castle, Delaware, USA). Samples were 
heated from 35 °C to 700 °C at a constant heating rate of 10 oC /min under nitrogen 
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atmosphere. ATR-FTIR (Nicolet 6700, Thermo Scientific) was used to investigate the 
cross-linked core-shell composites in the range of 500-4000 cm−1. 
5.2.4 Swelling behavior of gelatin hydrogel  
To evaluate the swelling behavior of the gelatin hydrogels, the dry hydrogel was 
weighed, then immersed in different buffer solutions with various pH's. Then, the wet 
hydrogel solution was poured onto a Petri dish for 30 seconds to eliminate the bulk 
solution. The wet samples were then weighed to measure the swelling ratio of the 
hydrogel. The effect of crosslinker amount on the swelling behavior of the gelatin 
hydrogel was evaluated to determine the releasing kinetics mechanism. The swelling ratio 
was calculated according to the following equation 
100% ×−=
d
dw
W
WWSwelling ,                                                                                           (5.1) 
where Ww and Wd represent the weights of wet and dry gelatin hydrogels, respectively. 
Each experiment was carried out in triplicate.  
5.2.5 Kinetic release studies of ac-Rb1 
The ac-Rb1 concentration encapsulated within the PLGA microspheres was measured 
using a UV spectrophotometer (Shimadzu UV-Vis 3600) in triplicate at 203 nm. First, a 
standard calibration curve of ac-Rb1 was established using the UV spectrophotometer by 
measuring the absorbance as a function of concentration. To measure the ac-Rb1 content 
after PLGA encapsulation,
 
5 mg of ac-Rb1-loaded microspheres was dissolved in 1 mL of 
DCM, which was subsequently evaporated with the residue then dissolved in 1 mL of 
methanol. The ac-Rb1 content was analyzed based on the calibration curve established 
from ac-Rb1 standard solution mixtures. To measure the release of ac-Rb1 from the core-
shell system, the crosslinked gelatin core-shells containing ac-Rb1-loaded PLGA cores 
were placed in a 6-well tissue culture plates (Corning), and incubated with PBS (pH=7.4) 
at 37ºC. At predetermined time intervals, the supernatant was removed from each well 
and replaced with fresh PBS. The ac-Rb1 content in the supernatant was determined at a 
wavelength of 203 nm using a UV spectrophotometer (Shimadzu UV-Vis 3600). All 
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experiments for each time interval were repeated in triplicate. The cumulative release of 
ac-Rb1 profiles were acquired with the volume loss correction. 
5.2.6 Bioactivity of released ac-Rb1 
The mouse macrophage cell line RAW 264.7 was cultured in Dulbeccos Modified Eagle's 
Medium supplemented with 10% FBS, 25 mM HEPES, 2 mM Glutamine, 100 IU 
penicillin/ml, and streptomycin 100 µg/mL. The pH of the medium was around 7.4. The 
cells were kept at 37°C in a humidified incubator with 5% CO2, and seeded in 96-well 
tissue culture plates at a density of 1.5×105 cells per well. Our previous study showed that 
ac-Rb1 has potency toward immunosuppressive activity on murine macrophages [16]. 
Also, based the results in Chapter 4, the preparation method of the PLGA microspheres 
does not have significant effect on the inhibitory effect of ac-Rb1. In this study, the 
inhibitory effect of released ac-Rb1 from the core-shell system in vitro was evaluated. To 
examine the inhibitory effect of released ac-Rb1, 5-150 µg/mL of ac-Rb1 and released ac-
Rb1 from PLGA microsphere/ gelatin hydrogel crosslinked 50 µL were added to the 
macrophages 2h prior to the addition of  LPS. In this study, dexamethasone (DEX) was 
used as a positive control for the suppression of LPS-induced stimulation of 
macrophages. So, cultured macrophages were incubated with DEX (5 µM) for 2 hr prior 
to the addition of LPS. The 24-hour cytokine production induced by LPS was determined 
by measuring NO and TNF-α levels in the culture medium. TNF-α concentrations in 
supernatants from cultured cells were analyzed with ELISA. Samples were assessed with 
mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, USA) according to 
the manufacturer's protocol. Sample nitrite concentrations in culture medium were 
determined by means of Griess reagent (0.5% sulfanilic acid, 0.002% N-1-naphtyl-
ethylenediamine dihydrochloride, 14% glacial acetic acid). Culture supernatant of each 
sample and the Griess reagent (50 µL each) were added to a 96-well plate. The 
measurements of absorbance were conducted at a wavelength of 550 nm using a 
Multiskan Spectrum microplate reader (Thermo Fisher Scientific, Finland) with SkanIt 
software (version 2.4.2, Thermo Fisher Scientific, Finland). Nitrite concentrations were 
calculated from a sodium nitrite standards calibration curve. 
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5.2.7 Statistics 
All experiments were performed at least three times with statistical analysis 
accomplished using GraphPad prism 4.0a Software (GraphPad Software Inc., USA). Data 
were reported based on mean ± standard deviation (SD) of three sets of experiments. 
Data sets with multiple comparisons were evaluated by one-way analysis of variance 
(ANOVA) with Tukey’s and Dunnett’s post-hoc test. p < 0.05 was considered to be 
statistically significant. 
5.2.8 Model fitting of in vitro release of ac-Rb1 
In order to investigate the kinetics of ac-Rb1 release from the PLGA microspheres as well 
as ac-Rb1 release from the PLGA microspheres/gelatin hydrogel combination system, 
four commonly used empirical models were used to fit the in vitro release data, i.e. the 
Hixson-Crowell, Korsemeyer-Peppas, Weibull and  first-order models [4, 33-35]. The 
curve fitting toolbox of Matlab R2010a software was used to determine both the 
regression coefficients, r2, and the best fit model parameters to understand the release 
mechanism for the studied systems. 
 
5.3 Results and Discussion 
5.3.1 Synthesis and characterization of the delivery systems 
PLGA microspheres loaded with ac-Rb1 were used in the preparation of core/hybrid 
composite delivery systems by adding gelatin and glutaraldehyde crosslinker. The 
morphology of the prepared delivery system containing the microspheres and the gelatin 
shell was examined by SEM and is shown in Figure  5.2. The morphology of the ac-Rb1-
loaded PLGA microspheres did not change after being entrapped in the gelatin. In 
addition, it can be seen from the SEM images that the microspheres were uniformly 
distributed within the gelatin hydrogel structure. 
 
 
  
Figure  5.2. Scanning Electon Microscopy results of 
from microfluidic method
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Figure  5.3. FTIR results for a) non-crosslinked and b) crosslinked gelatin hydrogel. The 
crosslinked hydrogel was prepared by using 100 uL of glutaraldehyde.  
In order to better understand the gelatin crosslinking reaction, DSC was carried out. As 
can be seen in Figure  5.4A, two glass-transition temperatures (Tg's) for gelatin are 
observed. The minor Tg is at 97°C which is related to the Tg of α-amino acid blocks in the 
peptide chain [36]. This Tg detection is complicated by moisture loss of the hydrophilic 
gelatin, which occurs in the same temperature range. The second Tg is at 135°C which is 
related to the blocks of imino acids, i.e. proline, hydroxyproline, and glycine, which 
mainly control the overall physical behavior of gelatin [36]. The two Tg's are shifted from 
97°C to 106°C and from 135°C to 155°C, respectively,  as a result of  crosslinking, which 
confirms the FTIR results.  
TGA analysis was used to further examine the crosslinking reaction between gelatin 
hydrogel and glutaraldehyde crosslinker (Figure  5.4B). The first weight loss of around 
5.5% and 5% happened in the temperature range of 35-135°C due to the loss of moisture 
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for non-crosslinked and crosslinked gelatin hydrogels, respectively. Additional weight 
loss occurred from 135-450°C due to breaking the polymer linkages and decomposition 
of the polymer backbone. Weight losses of around 65% and 59% were observed at 400°C 
for the non-crosslinked and crosslinked gelatin hydrogels, respectively. The addition of 
glutaraldehyde to the gelatin network increased the thermal stability of the gelatin 
hydrogel slightly, which is in agreement with the literature on the thermal degradation 
behavior of crosslinked proteins [39, 40]. 
 
Figure  5.4. A) DSC thermograms of non-crosslinked (dash blue line) and crosslinked 
gelatin hydrogel (solid red line).  B) TGA traces of non-crosslinked (dash blue line), and 
crosslinked gelatin hydrogel (solid red line). The crosslinked hydrogel was prepared by 
using 100 µL of glutaraldehyde.  
For potential application of these materials in oral formulations, for instance, ginsenoside 
Rg3 has been shown effective in colon cancer [41] and our previous results using ac-Rb1 
showed anti-angiogenic and immunoactivity activities [16], swelling behaviour is of 
interest. The swelling performance of the gelatin hydrogel was studied with respect to the 
amount of crosslinker and also at different pH values. Figure  5.5A shows the swelling 
behavior of gelatin hydrogel in PBS (pH 7.4) as a function of time (t) prepared with 
different amounts of crosslinker. The results show that swelling significantly increased 
with time up to 300 min, which then reaches a maximum. Also, the gelatin hydrogel 
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swelling decreased upon increasing the degree of crosslinking attributed to a decrease in 
porosity and polymer chain elasticity of the hydrogels by adding crosslinker. Highly 
crosslinked hydrogels have a hardened matrix and show additional resistance to the 
penetration of water due to their network structure. These results are in good agreement 
with the literature showing that swelling of gelatin sponge decreased with an  increasing 
degree of crosslinking [28]. Moreover, the swelling behavior of gelatin hydrogels 
containing ac-Rb1-PLGA microspheres was investigated at different pH values including 
1.2, 4.5, and 7.5 (Figure  5.5B). The results show that all systems gave similar swelling 
behavior; however, they revealed different water affinity at different pH values, attributed 
to the pendant acidic groups on the polymeric chains [42]. At the lowest pH investigated, 
i.e. 1.2, the acidic pendant group of gelatin was un-ionized (-COOH) so the water affinity 
was low. When the pH was increased to 7.4, the hydrogel swelled gradually with the 
increased pH due to ionization of acidic groups, i.e. forming -COO− ions. 
 
A) 
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Figure  5.5. Swelling behavior of gelatin hydrogels: A) effect of glutaraldehyde 
crosslinking concentration; B) effect of solution pH. Releasing medium was PBS at 
37°C.  
5.3.2 In Vitro ac-Rb1 release and release kinetics  
The release profile of ac-Rb1 from the core-shell structures are examined and compared 
in Figure  5.6. The release behavior was monitored for 400 hr at pH = 7.4. The non-
crosslinked gelatin hydrogels containing ac-Rb1 swelled and dissolved in the release 
medium, with around 80% of ac-Rb1 released within 1 h (Figure  5.6A-a). The release 
profile of ac-Rb1 from the non-crosslinked gelatin hydrogels remained constant and at the 
same level for the entire release time. The release profile from the cross-linked gelatin 
hydrogels containing ac-Rb1-PLGA microspheres was slow (Figure  5.6A-c). These 
results are in accordance with the reported results on bovine serum albumin (BSA), a 
model protein drug, where the investigators utilized PLGA microspheres prepared by a 
double emulsion method, encapsulated within alginate hydrogels. Their results showed 
that almost 10% of BSA was released from the combined system after 10 h (initial burst) 
whereas 25% of BSA was released after 2 weeks [29, 30]. Our results show a smaller 
burst effect (less than 10% within 10 h) attributed to the utilized monodisperse PLGA 
microsphere cores. In comparison with Figure  5.6A-b which consisted of ac-Rb1 
encapsulated PLGA microspheres, the initial burst effect and the releasing rate decreased. 
B) 
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Our results (Figure  5.6B) indicate that increasing the crosslinker amount decreased the 
ac-Rb1 release rate. This is attributed to the cross-linking reaction hardening the gelatin 
matrix, as shown by FTIR, DSC and TGA, which would enhance the resistance of ac-Rb1 
release. As a result, increasing the amount of crosslinker decreased the ac-Rb1 diffusivity 
through the delivery system. Thus, the total cumulative ac-Rb1 release from the cross-
linked gelatin hydrogels containing ac-Rb1-PLGA microspheres was adjustable by 
controlling the amount of crosslinker, resulting in 24 - 35% release of ac-Rb1 after 400 h. 
Therefore, ac-Rb1-PLGA microspheres-gelatin hydrogels can provide a powerful system 
for controlling the  release for longer periods of time, which may have application for 
cancer treatment using implantable devices or for transdermal patches. 
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Figure  5.6. Release profiles of ac-Rb1 from various delivery carriers; A) a)* gelatin 
hydrogel without crosslinker; b)●PLGA microsphere obtained by microfluidic method; 
c)▲PLGA microsphere produced by microfluidic method / gelatin hydrogel crosslinked 
by 50µL GA; B) a)■PLGA microsphere/ gelatin hydrogel crosslinked by 10µL GA; 
b)▲PLGA microsphere/ gelatin hydrogel crosslinked by 50µL GA; c)▼PLGA 
microsphere/ gelatin hydrogel crosslinked by 100µL GA. Releasing medium was PBS 
(pH=7.4) at 37°C. 
5.3.3 Bioactivity of released ac-Rb1 
Our results previously showed that ac-Rb1 ginsenoside has potent immunosuppressive 
effects [16]. For the current study, the immunosuppressive activity of released ac-Rb1 
was examined by bioassay analysis using macrophages in vitro. The effect of ac-Rb1 
treatment on LPS-stimulated NO and TNF-α production in macrophages can be seen in 
Figure  5.7. This figure shows that ac-Rb1 released from the PLGA microspheres/gelatin 
hydrogel carrier significantly inhibits the production of NO and TNF-α, in LPS-induced 
RAW 264.7 macrophages. This inhibition occurs in a dose-dependent manner within the 
dose range of 5-150 µg/mL released ac-Rb1 extract. The immunosuppressive activity of 
ac-Rb1 did not change significantly before encapsulation within carrier and after release 
from the delivery carrier.  This indicates  that the combination delivery system did not 
B) 
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significantly affect the immunosuppressive activity of ac-Rb1. Figure  5.7 also represents 
that the influence of ac-Rb1 is inflammatory mediator-specific i.e. the magnitude of 
inhibition by ac-Rb1 before encapsulation and after release from the combination delivery 
carrier was much greater with respect to NO production. The ac-Rb1 released from the 
delivery system of monodisperse PLGA microspheres combined with gelatin hydrogel 
after 400 h, inhibited the LPS-induced NO production more significantly with the lowest 
level of NO production around 7 µM in presence of 150 µg/mL released ac-Rb1. In fact, 
the combination delivery system presents a promising tool of immunosuppressive ac-Rb1 
product delivery for next-generation biomedical agents in drug-release devices.  
 
 
Figure  5.7. Inhibitory effect of ac-Rb1 on LPS-stimulated 24 hr macrophage production 
of  a) NO and b) TNF-α. Murine macrophages (RAW 264.7 cells) were pre-treated with 
the ac-Rb1 ginsenoside and dexamethasone (DEX) for two hours after which LPS (1 
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µg/mL) was added, and the culture supernatants were analyzed for NO and TNF-α by 
Griess reaction assay and ELISA, respectively. Dexamethasone (DEX) at 5 µM was used 
as a positive control. Three independent experiments were performed and the data were 
shown as mean ± SD. Datasets were evaluated by ANOVA. #Values p<0.05 Significantly 
different from LPS-induced group. 
5.3.4 Analysis of release data 
To better understand the release mechanism from the microspheres and core-shell 
structures, we fit the ac-Rb1 release curves from Figure 5.6 in Matlab™ to determine if 
the release behavior is controlled by Fickian diffusion, erosion or a combination of both. 
Four well known empirical models were examined, i.e. the Hixon-Crowell, Korsmeyer-
Peppas, Weibull, and first-order models [4, 33-35]. According to the r values shown in 
Table  5.1, the Weibull model provides the best fit for the ac-Rb1 release experimental 
data for all the examined delivery systems. The curves of the best fitting and the linear 
regression lines from the Weibull model are shown in Figure  5.8. 
Table  5.1. The release model parameters of different carriers for ac-Rb1 pH=7.4 
polydisperse microsphere= Poly-MS; monodisperse microsphere= Mono-MS; 
glutaraldehyde= GA. 
 Model Equation r2 SSE 
Poly-MS 
First-order (1 − ∞) = −0.0064     -0.454 6.447 
Hixon-Crowell (1 − ∞)
  = 0.778 − 0.0007 0.642 0.091 
Korsmeyer-Peppas (∞) = −1.392 + 0.226 0.898 0.323 
Weibull [
1
1 − ∞
] = −1.178 + 0.3147 0.963 0.211 
Mono-MS 
First-order (1 − ∞) = 0.0033     -135.5 7.679 
Hixon-Crowell (1 − ∞)
  = 0.936 − 0.0004 0.849 0.008 
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Korsmeyer-Peppas (∞) = −2.639 + 0.3301 0.994 0.0367 
Weibull [
1
1 − ∞
] = −2.646 + 0.3779 0.995 0.0488 
gelatin hydrogel First-order  1 − ∞ = −1.841 − 0.003 
0.529 2.405 
Hixon-Crowell (1 − ∞)
  = 0.5484 − 0.00051 0.459 0.089 
Korsmeyer-Peppas (∞) = −0.3567 + 0.0562 
0.784 0.061 
Weibull [ 1
1 − ∞
] = 0.193 + 0.1493 0.908 0.159 
Microsphere/gelatin 
hydrogel 50µ GA 
First-order  1 − ∞ = −0.09701 − 0.0011 
0.854 0.058 
Hixon-Crowell (1 − ∞)
  = 0.9682 − 0.00033 0.843 0.006 
Korsmeyer-Peppas (∞) = −3.879 + 0.509 
0.980 0.368 
Weibull [ 1
1 − ∞
] = −3.896 + 0.543 0.986 0.299 
 
Almost comparable fitting with the Weibull model was observed in the case of using the 
Korsmeyer-Peppas model for ac-Rb1 release from the core-shell combination system; 
however the fit was not as good for the ac-Rb1 release from Poly-MS and gelatin 
hydrogel without crosslinker. A poor fitting was obtained by using the first order and 
Hixson-Crowell equations, which showed that they are not proper models for the systems 
of this study. From Table  5.1 and Figure  5.8, the slope of the regression line of the 
Weibull model is the constant b. According to the literature [43], for values of b lower 
than 0.75, the release follows Fickian diffusion whereas for b >0.75, other mechanisms 
such as erosion better describe the release. In this study, the results indicate that this 
value for the Poly-MS, Mono-MS, the gelatin hydrogel without crosslinker system and 
PLGA- gelatin hydrogel combination system is 0.31, 0.38, 0.15 and 0.54, respectively as 
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can be seen in Table  5.1. Therefore, the diffusion mechanism controlled the release of ac-
Rb1 within the studied time-frame as best described using the Weibull and Peppas models 
[35, 44] and can be used for a long term drug delivery applications.  
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Figure  5.8. Release profiles (left) and fitting regression lines (right) by Weibull kinetic 
model for a, b) ac-Rb1 release from PLGA microsphere produced by conventional 
method, c, d) ac-Rb1 release from PLGA microsphere produced by microfluidic method, 
and e, f) ac-Rb1 release from PLGA microsphere crosslinked gelatin hydrogel 
combination system. 
 
5.4 Conclusions 
The ac-Rb1 loaded PLGA microspheres with the narrowest size distribution were 
incorporated into gelatin hydrogels for the development of bioactive natural extract 
ginsenoside ac-Rb1 delivery system. The crosslink reaction of gelatin and glutaraldehyde 
was confirmed by FTIR, DSC and TGA. The slower and more sustained release profile is 
represented by the combination of microsphere crosslinked hydrogel delivery systems in 
comparison with the non-crosslinked system. The in vitro release kinetics data followed a 
Fickian trend with the best fit observed with Weibull model. Furthermore, the released 
ac-Rb1 from PLGA/gelatin system showed immunosuppressive effect on LPS-induced 
macrophages which confirmed that the combination delivery system could retain the 
immunosuppressive activity of ac-Rb1. This novel system could be a promising tool for 
bioactive plant extract ac-Rb1 delivery with immunusuppressive activity. 
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Chapter 6  
 
6 Conclusions and Recommendations 
 
6.1 Conclusions 
 
Ginseng root has been used for thousands of years in Eastern medicine and is one of the 
best-selling medicinal plants in the world [1]. Panax ginseng (Korean or Asian), Panax 
quinquefolius (American) are the two most well-known ginseng varieties around the 
world [2]. Although significant research is available on Asian ginseng [1, 2], the study of 
American ginseng and its components is not well reported. Like Asian ginseng, American 
ginseng is reported to have a variety of pharmacological effects, including effects on the 
central nervous system, cardiovascular system, immune system and cancer treatment [1, 
3]. The qualitative and quantitative studies of bioactive compounds from medicinal plants 
such as ginseng mostly depend on the choosing of the appropriate extraction method [4, 
5]. Extraction is the first step of any medicinal plant study that has an important role on 
the final result. Moreover, different chromatographic and spectrometric methods have 
been reported as a significant aid to the analysis and characterization of bioactive 
compounds obtained from extraction methods [6-10]. In recent years, different ginseng 
extracts are being used as nutraceutical and supplements world-wide. Also novel 
formulations have been reported for delivery of bioactive compounds extracted from 
medicinal herbal plants in order to deliver the bioactive plant extract to specific sites of 
action [11, 12]. 
In this study, the ultrasound assisted extraction method was used for extraction of 
ginsenosides from North American ginseng with DMSO and methanol as solvents at 
ambient temperatures from 25-33°C. Ginsenosides are believed to be thermally unstable 
compounds, therefore using a proper extraction method is important to obtain 
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ginsenosides which are bioactive. Our results showed that the choice of solvent has a 
significant effect on extraction of specific bioactive ginsenosides. Both DMSO and 
methanol were effective solvents for ultrasonic extraction of ginsenosides. However, 
DMSO showed higher extraction and better selectivity with a total ginsenoside yield of 
almost 10 (%, w/w) compared to a total ginsenoside yield of almost 8 (%, w/w) when 
using methanol as solvent. Moreover, aqueous solvents were found to increase the 
extraction efficiency in comparison with the pure solvents, with the best extraction 
efficiency obtained using 80/20 vsolvent/vwater. Furthermore, large quantities of acetyl 
ginsenoside Rb1 were found using ultrasonic extraction with DMSO, which was 
negligible in the case of using methanol and was not obtained using Soxhlet methanol 
extraction. Therefore, the presence of acetyl ginsenoside Rb1 is related to the effect of 
extracting solvent and attributed to the high solubility parameter and temperature stability 
of DMSO. Although the solubility of acetyl ginsenoside Rb1 is a complex phenomenon, 
the individual components of the solubility parameter of DMSO provide insight into how 
DMSO is a more effective solvent for extraction of acetyl ginsenoside Rb1. 
The large quantity of acetyl ginsenoside Rb1 that were found using ultrasonic extraction 
with DMSO was fractionated and isolated using a preparative HPLC column and 
subsequently identified by MS, FTIR, and NMR as 6”-O-acetylginsenoside Rb1. This 
compound was then tested for immunomodulation and anti-angiogenesis effects. Both 
80% DMSO ginseng extracts and 80% methanol ginseng extracts were found to inhibit 
the production of NO and TNF-α in LPS-induced RAW 264.7 macrophages in a dose-
dependent manner with higher dose resulting in better inhibition. However, the DMSO 
extract caused more inhibition than the methanol extract for the production of NO and 
TNF-α in LPS-induced RAW 264.7 macrophages. This was attributed to the presence of 
more acetyl ginsenoside Rb1 in the DMSO extract which significantly inhibited the 
production of NO and TNF-α in LPS-induced RAW 264.7 macrophage cells in a dose-
dependent manner within the dose range of 5-150 µg/mL. Acetyl ginsenoside Rb1 was 
also shown to have anti-angiogenic properties and exhibited potency towards inhibiting 
tube-like structure formation in endothelial cells. These findings suggest that the presence 
of the acetyl moiety has influence on biological activity. 
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Moreover, supercritical fluid chromatography coupled with an evaporative light 
scattering detector was employed in the separation of the SFE extracts of North American 
ginseng with 15-31% of methanol in supercritical CO2 as the mobile phase. Pure CO2 
was a poor mobile phase for separation of the polar components of North American 
ginseng extract, particularly for the ginsenoside components of interest. This is attributed 
to the low solubility of the polar ginsenosides in pure CO2. The effect of temperature and 
pressure on the separation of mixture of ginsenoside standard was tested with the best 
condition being found at T=50°C and P=150 bar. The retention time of the ginsenosides 
was altered by tuning the pressure and temperature. Under a constant pressure, the 
density of the mobile phase decreased with increasing temperature, leading to a lower 
solvating power of the mobile phase. The lower solubility of the ginsenosides in the 
mobile phase resulted in longer retention times. The retention time of all the ginsenosides 
decreased with increasing pressure from 100 to 200 bar at a constant temperature of 
50°C. However, under a constant temperature, increasing pressure resulted in increased 
density and solving power of the mobile phase, leading to a shorter retention time. The 
effect of three types of additives including acidic TFA, basic DIPA, and ionic AA 
aqueous solution on the separation efficiency was examined, with the best selectivity 
being found in the case of the addition of 0.05% v/v TFA in methanol. By adding varying 
amount of additives, the retention time changed indicating the varying solubility of the 
extract fractions. A high-concentration fraction in the SFE extracts of North American 
ginseng was isolated with the SFC system and characterized with NMR, HPLC-RID, and 
ESI-MS. The identity of this unknown peak was confirmed to be the disaccharide 
sucrose, which has not been reported.  
Research on ginsenoside delivery and release is of interest due to their unique biological 
activity. A new approach for a bioactive ginseng extract of acetyl ginsenoside Rb1 
delivery is presented. Encapsulation of acetyl ginsenoside Rb1 within PLGA 
microspheres was performed with both a conventional double emulsion method and a 
microfluidic method. SEM and light microscopy analysis showed that all microspheres 
have similar spherical morphology, although the microfluidic approach produced more 
uniform size spheres (50-65 µm) compared to the more polydisperse microspheres from 
the w/o/w emulsion method (10-70 µm). The monodisperse microspheres produced by 
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the microfluidic method (50-65 µm) were found to exhibit a slower release rate and a 
smaller burst effect than polydisperse microspheres formed by the double emulsion 
method (10-70 µm). These microspheres can be used for drug delivery applications to 
maintain a therapeutic agent concentration for an extended time period. DSC was used to 
study of the thermal behavior of ac-Rb1-loaded PLGA microspheres. Also, the XRD of 
ac-Rb1-loaded PLGA showed that ac-Rb1 is entrapped within PLGA microspheres in an 
amorphous state. DSC and XRD of the microspheres confirmed the molecular-level 
uniform distribution of ac-Rb1 within the PLGA polymer. Moreover, a new delivery 
system consisting of PLGA microspheres embedded within gelatin hydrogels was 
developed for natural extract ginsenoside ac-Rb1 delivery in vitro. The chemical 
interactions between gelatin hydrogel and crosslinker (glutaraldehyde) was confirmed by 
FTIR. The combination of microsphere crosslinked hydrogel delivery systems gave a 
lower burst effect and more sustained release than gelatin hydrogel without crosslinker. 
Also, in comparison with our previous system which consists of ac-Rb1 encapsulated 
PLGA microspheres, the initial burst effect decreased. Moreover, the combination 
delivery systems' swelling behavior and release profiles were effected by the pH of the 
medium. At lower pH values i.e 1.2, gelatin's acidic groups remain un-ionized so gelatin 
shrinks gradually and the amount of cumulative release is decreased. However, by 
increasing the pH to 7.4, the weakly acidic gels become ionized leading to network 
swelling, increasing the release of ac-Rb1. Also, Four empirical models, Hixon-Crowell, 
Korsmeyer-Peppas, Weibull, and first-order models [13-16] were used to fit the ac-Rb1 
release curves. The in vitro release kinetics data followed a Fickian trend with the best fit 
observed using the Weibull model.  This indicates that the release mechanism is governed 
by diffusion during ac-Rb1 release. Acetyl ginsenoside Rb1 released from the 
combination delivery system was shown to give potency towards inhibition of NO and 
TNF-α production in LPS-induced macrophages. Hence, the combination delivery system 
presents a promising tool of immunosuppressive ac-Rb1 product delivery for next-
generation biomedical agents in drug-release devices. 
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6.2 Recommendations 
The following recommendations will be useful in the future investigations of this study: 
i) As the acetyl ginsenoside Rb1 solubility in DMSO and methanol is a complex 
phenomenon, further investigation such as using vibrational circular dichroism 
(VCD) spectroscopy, in combination with density functional theory (DFT) 
calculations is required to consider other physicochemical properties of solvents 
and solute. 
ii) Acetyl ginsenoside Rb1 shows immunosuppressive and anti-angiogenesis 
activities on macrophages and human cell lines, respectively. Further in vivo study 
of acetyl ginsenoside Rb1 can be evaluated. 
iii) Different SFC columns such as Ethylpyridine (2-Ethylpyridine-bonded silica), 
Diol (Propanediol-bonded silica), and Amino (Aminopropyl-bonded silica) can be 
used in comparison with Cyano (cyanopropyl-bonded silica) column to evaluate 
separation of polar and non polar components of North American ginseng extract. 
iv) Different SFC columns can be used in series to evaluate ginseng extracts 
separation. 
v) The online mass identification of ginseng extracts can be evaluated by coupling 
SFC system with mass spectroscopy detector. 
vi) The supercritical fluid chromatography of ginsenosides and other ginseng extract 
can be investigated quantitatively. 
vii) PLGA with different molecular weight and different ratios of monomer can be 
studied to examine the release behavior to target release for specific disease 
treatments. 
viii) Detailed study on microfluidic droplet formation and the effects of microchip 
geometry on microsphere size can be simulated with computational fluid 
dynamics (CFD). 
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ix) Rather than empirical mathematical models for studying the mechanism of acetyl 
ginsenoside Rb1 release, mechanistic mathematical modeling which are based on 
real phenomenon such as diffusion, degradation, and erosion can be used to 
understand the release process. 
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Appendices  
 
Appendix A. Purity (%) of 6”-O-acetylginsenoside Rb1. 
The purity of 6”-O-acetylginsenoside Rb1 was measured by HPLC system, using semi-
preparative Atlantis T3 Waters column (10 x 250 mm with 5µm packing) at room 
temperature. A full loop injection was employed (100 µL) with the flow rate set at 4 
mL/min and 6”-O-acetylginsenoside Rb1 peak was detected by a UV detector at 203 nm. 
The mobile phase was a binary gradient of acetonitrile (A) and HPLC grade filtered water 
(B) at a constant composition of 35% (A) for 2 min followed by a linear gradient to 45% 
from 2–12 min. The column was flushed and equilibrated for 35 min before each 
analysis. Fractions obtained were evaporated under vacuum to isolate the unknown 
extract, 6”-O-acetylginsenoside Rb1. Then, 6”-O-acetylginsenoside Rb1 was re-injected to 
the system to calculate the purity based on the peak areas: 
)*+"% = 	-.”01023456789:;4:<;9=4	>?	∑-  (A.1) 
6”-O-acetylginsenoside Rb1 (purity, >99%): White powder, mp 54 °C, ES-MS (m/z) 
1149.66. 
Note: Retention time shifted slightly by 0.28% - 10% for all individual ginsenoside 
standard and ginsenoside in ginseng extract. 
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Appendix B. Effect of methanol concentration on the retention 
of ginsenosides standard mixture at 50°C, 150 bar and a flow 
rate of 1.5 mL/min.  
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Appendix C. Dimensionless number’s calculations. 
The Reynolds number is defined as  
Re = ρud/µ ,                         (C.1)  
where ρ denotes the density of the continuous phase, u is the average velocity of the 
continuous phase, d is the hydraulic diameter and µ  is the viscosity of the continuous 
phase. The hydraulic diameter is defined as 
d = 4A / P ,                        (C.2) 
where A and P denote the cross sectional area and the wetted perimeter of the cross-
section, respectively. The definitions for A and P take the form 
A = h × w  ,                          P = 2 (h + w) ,               (C.3a,b) 
where h and w denote the height and width of the cross-section, respectively. The average 
velocity of the continuous phase can be calculated as follows 
u = Q / A ,             (C.4) 
where Q is the flow rate of the continuous phase. For 2% PVA aqueous solution the 
density and viscosity are ρ = 997.05 (kg/m3), µ  = 8.957 × 10−4 (kg/(m.s)). For instance, if 
Q = 0.1 (mL/min), h = 0.1 (mm) and w = 0.2 (mm), the values for the average velocity 
and the Reynolds number can be calculated in the form  
)s/m(0833.0)m(102.01.0
)s/m(60/101.0
26
36
=
××
×
=
−
−
u  ,                    (C.5) 
37.12)m.s)/(kg(10957.8
)m(101333.0)s/m(083.0)m/kg(05.997
4
33
=
×
×××
=
−
−
Re  .      (C.6) 
The capillary number is defined as 
Ca = µu/γ  ,                                   (C.7) 
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where γ is the interfacial tension between the oil and water phases. The value of the 
interfacial tension for the materials experimented in this dissertation is γ = 0.022 (N/m). 
A sample calculation for the capillary number for the above parameters takes the form 
Ca = [8.957 × 10−4 (kg/ms) × 0.083 (m/s)] / [0.022 (N/m)] = 0.0034 .      (C.8) 
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